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Malaria is a life-threatening disease caused by Plasmodium spp. parasites. Although Plasmodium 
falciparum is the deadliest form of malaria, Plasmodium vivax is the most globally widespread, with 
40 % of the world’s population at risk of infection. P. vivax is particularly difficult to diagnose and 
treat, an issue that is confounded by a lack of a continuous in vitro culture method. Without the ability 
to culture P. vivax, our knowledge of this important parasite has lagged behind P. falciparum (which 
has had a well-established in vitro culture method available since the 1970s).  
The recent re-establishment and optimisation of a continuous in vitro culture method for P. vivax’s 
sister taxon, Plasmodium cynomolgi (a vivax-like parasite found in old world monkeys) however, has 
for the first time allowed the mechanistic investigation of key biological processes, such as P. vivax 
biology (as it shares many of its distinct phenotypic characteristics), and the molecular basis for drug-
resistant P. vivax (as it has a high degree of genetic similarity). Without a continuous culture method, 
previous studies in these areas have had to rely on ex vivo and clinical drug susceptibility studies to 
investigate P. vivax drug resistance. Reverse genetic studies in P. cynomolgi will for the first time 
provide the ability to validate putative drug resistance markers in P. vivax, a crucial early step in 
mitigating the further emergence and spread of drug resistance through South-East Asia. 
To date the only published report on P. cynomolgi transfection involved episomal plasmids in an in 
vivo model (monkey infection). Our laboratory has focused on the establishment and optimisation of 
an in vitro integrative transfection protocol for P. cynomolgi; using a ‘one plasmid’ CRISPR-Cas9 
system adapted from the Fiddock Lab (University of Columbia, USA). This system was used to 
investigate validated molecular markers of P. falciparum drug resistance (the Y268S mutation in 
pfcytb, and the K76T mutation in pfcrt) and whether they would confer drug resistance in P. 
cynomolgi, as a model for P. vivax. We have been able to develop CRISPR plasmids for the Y268S 
mutation in cytochrome b (cytb) which is suspected to confer atovaquone resistance to parasites. The 
isolation of the P. cynomolgi crt gene was difficult however, and this, combined with the challenge 
of understanding transfection efficiency, led to a decision to try a second approach to the transfection 
of the crt gene. A plasmid containing cas9 and the gRNA was produced and was transfected into P. 
cynomolgi parasites alongside a single stranded oligodeoxynucleotide repair template.  
For the transfection of P. cynomolgi to be successful, there needs to be optimal culture conditions for 
parasites, to encourage growth and prevent contamination. Throughout our study, P. cynomolgi has 
proven to be an excellent model for P. vivax, however there are still obstacles associated with P. 
cynomolgi in vitro culture that need to be overcome in order to allow more efficient, ethical, and 
 vi 
cheaper culturing of these parasites.  To reduce costs and increase culture volumes, we investigated 
several serum combinations as alternatives to non-human primate serum. We also investigated 
antibiotic combinations to prevent bacterial contamination of cultures and sought to optimise the 
synchronisation of parasites (a key component of the transfection procedure).  
Finally, we sought to investigate the roles of the dbp1 and dbp2 genes in P. vivax invasion of RBCs 
by tagging these proteins with GFP to visualise them under electron microscopy. We were able to 
successfully construct a plasmid to tag the dbp2 gene in P. cynomolgi.  
Our laboratory has been able to show that P. cynomolgi is a tractable P. vivax model, receptive to 
genetic manipulation by CRISPR-Cas9. This work is the first of its kind for P. cynomolgi, but still 
requires further optimisation before it is available as a toolbox for further research into the neglected 
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CHAPTER 1 - INTRODUCTION 
  
 2 
1.1  Epidemiology 
Malaria is a life-threatening disease caused by the Plasmodium genus of unicellular eukaryotes, which 
are obligate parasites of vertebrates and insects (1). In 2019, there was estimated to be 229 million 
clinical cases and 409, 000 deaths due to malaria worldwide, with the highest incidence reported in 
Africa (94 %), followed by Southeast Asia (3 %) (2).  It should be understood that given the limited 
sensitivity and specificity of most current diagnostics to P. vivax, it can be reasonably assumed that 
these figures are significantly underestimated in the current literature. 
Of the Plasmodium species (spp.), four are responsible for human malaria: Plasmodium falciparum, 
Plasmodium vivax, Plasmodium malariae, and Plasmodium ovale.  However, the simian parasites 
Plasmodium cynomolgi and Plasmodium knowlesi have recently been reported to cause zoonotic 
malaria. To our knowledge, there have been no reports of human to human transmission of these latter 
two parasites (3-8).  
P. falciparum and P. vivax cause most malaria infections in humans (9). Although P. falciparum is the 
most prevalent cause of malaria, P. vivax is the most globally widespread (with ~95 countries being 
P. vivax endemic), putting over 40 % of the world’s population at risk of infection (9-12). The difference 
in the distribution of P. falciparum and P. vivax is primarily due to climate, and its effects on parasite 
development in the mosquito vector (13, 14). P. vivax’s ability to form a dormant liver parasite 
(hypnozoite) allows protection from the host immune system during the long mosquito-free cold 
seasons, when onward transmission and propagation is not feasible (15, 16). 
While over the past 15 years there have been significant reductions in malaria morbidity worldwide; 
the last five years have seen these gains plateau due to the increasing prevalence of antimalarial drug 
resistance (9).  The extensive use (and misuse) of antimalarial drugs has resulted in the emergence of 
drug resistance in human malaria strains.  This emergence of drug resistance is a significant 
contributor to the global resurgence of malaria (17, 18). Clearly, there is a need for new antimalarials 




1.2  Plasmodium life cycle 
The development of strategies to treat and prevent malaria requires an understanding of the complex 
life cycle of Plasmodium spp. parasites (Figure 1.1). Infection begins when an infected female 
Anopheles mosquito takes a blood meal, injecting sporozoites intradermally into the skin and the 
surrounding microvasculature (19-21).  Sporozoites migrate to the liver and infect hepatocytes, initiating 
the exo-erythrocytic stage of infection (20, 22, 23). The parasites develop into liver schizonts and rupture, 
releasing merozoites into circulation to infect red blood cells (RBCs) and initiate the erythrocytic 
stage of infection (7, 20, 22-28). In some species of Plasmodium spp. (such as P. vivax and P. cynomolgi), 
hypnozoites may form and remain in the liver until they reactivate to cause a relapse of infection (23-
25, 29-34).  Hypnozoites causing relapse may reactivate weeks to months after the initial infection. It is 
believed that reactivation is triggered by external stimuli such as another malaria infection or other 
infectious diseases (35, 36). The length of latency has also been shown to have a geographical 
distributionwith tropical P. vivax having short (~3 weeks) latency periods, compared to temperate P. 
vivax infections which are often characterised by long (8-10 months) latency periods (37, 38).  
A small number of parasites will exit the blood-stage, developing into gametocytes, which can infect 
a new mosquito and thereby be transmitted to other hosts (20, 24, 39-42). Once taken up by a mosquito, 
the gametocytes go through their sexual reproduction cycle. This takes ~10-14 days resulting in the 
production of thousands of sporozoites that migrate to the salivary glands of the mosquito, where 

















1.3 Plasmodium vivax invasion biology 
P. vivax merozoite invasion of RBCs (Figure 1.2) is a complex multi-stage process between parasite 
and CD-71 positive reticulocytes. By chance the free P. vivax merozoite will encounter a circulating 
RBC. The initial merozoite attachment to RBCs is facilitated by a family of Merozoite Surface 
Proteins (MSPs) that cover the merozoite surface (45, 46). Specifically MSP1 functions to form a 
platform that allows assembly of a large protein complex that holds other MSPs that play a role in 
initial attachment (as explained below) (47).  
Following attachment, there is secretion of proteins from the apical organelles (the micronemes and 
rhoptries) which creates a gradient of proteins involved in invasion on the merozoite surface. These 
proteins are most densely concentrated at the apical tip. The interaction of these proteins with the 
RBC surface exceeds the affinity of the initial MSP interactions, causing the merozoite to re-orient 
onto its apex without any energetic input (48).  
The initial tight interaction with the RBC is mediated by two major families of adhesins, the 
erythrocyte binding ligand (ebl) and reticulocyte-binding protein (rbp) gene families (46). The ebl 
genes encode for Duffy-binding proteins (DBPs) and are responsible for binding to the Duffy antigen 
receptor for chemokines (DARC) on monkey and human RBCs (49-51). The DBP and DARC 
interaction in P. vivax and P. cynomolgi is necessary for invasion of host RBCs (50, 52). Interestingly, 
P. cynomolgi has 2 of these dbp genes, whereas P. vivax only has 1 dbp gene. It has been hypothesised 
that P. vivax has lost its ability to infect Old World Monkey erythrocytes due to losing one of these 
dbp genes. The presence of these 2 dbp genes has allowed P. cynomolgi to retain its ability to invade 
human erythrocytes (50). While most of these proteins individually appear non-essential, their function 
overall is required for invasion.  
A tight junction is formed between the merozoite and the reticulocyte. A molecular bridge is formed 
between the merozoite surface and the RBC. As the merozoite enters the cell, this tight junction 
moves rearward along the merozoite, forcing the parasite into the parasitophorous vacuole membrane 













1.4 Unique biological characteristics of Plasmodium vivax 
The biological differences between P. falciparum and P. vivax have implications for pathogenesis, 
treatment options, and long-term in vitro culturing. P. vivax tropism is restricted to nascent (CD-71 
positive) reticulocytes, which has been identified as a key limitation in the development of an in vitro 
continuous culture method for P. vivax (29, 54, 55).   
P. vivax gametocytes are transmissible at a lower parasitaemia than P. falciparum, being detectable 
as early as 3-5 days after their appearance in the liver, compared to 10 days for P. falciparum (24, 41, 
56). This means the transmission of P. vivax gametocytes can occur before the presentation of clinical 
symptoms of infection (40, 57-59). The early gametocytogenesis and shorter gametocyte lifespans 
contributes to drug resistance appearing less frequently in P. vivax populations, as patients are often 
beginning treatment after transmission of the parasite has already begun (59-61). 
Following drug treatment, the reappearance of P. vivax infection (reoccurrence) can have 1 of 3 
origins; recrudescence (true drug resistance), reinfection, or relapse (reactivation of hypnozoites), and 
it is difficult to distinguish among these (30, 42, 62, 63). Hypnozoite production is an important 
characteristic of P. vivax as relapses, caused by random re-activation of hypnozoites weeks to months 
after parasite clearance from the blood, make it difficult to distinguish the origin of recurrence of P. 











1.5  Evolutionary biology of Plasmodium species 
1.5.1 Plasmodium falciparum and Plasmodium vivax   
 Both P. falciparum and P. vivax have evolved from parasites that infect wild-living African 
apes. However, P. falciparum and P. vivax are not closely phylogenetically related. Human P. 
falciparum is believed to have originated as a result of the cross-species transmission of a parasite 
that had previously diversified in African gorillas (66, 67).  It is believed that extant P. vivax emerged 
from parasites that infected chimpanzees, gorillas, and humans in Africa.  Duffy glycoproteins (such 
as DARC) act as receptors for P. vivax (68).  Duffy-negative populations are common in Africa, 
resulting in RBCs that are relatively resistant to invasion by P. vivax (69, 70). However, the recent 
discovery of P. vivax Duffy independent strains, that are found in Madagascar and parts of Africa are 
likely the result of a reintroduction of the parasite from Asia (66, 71).  
 
1.5.4 Plasmodium knowlesi and Plasmodium vivax 
 In contrast to P. falciparum, P. knowlesi is not genetically distanced to P. vivax, with ~90 % 
of genes being shared between both P. vivax and P. knowlesi (Figure 1.3) (50, 72, 73).  P. knowlesi is a 
simian malaria parasite that was initially thought to be restricted to macaques in Southeast Asia (3). It 
has recently been recognised as a significant cause of human malaria, with a large number of naturally 
acquired cases identified in 2004 (74, 75). Like P. vivax, Duffy blood group negative human RBCs are 
resistant to infection by P. knowlesi (76). Unlike the benign and morphologically similar human 
parasite Plasmodium malariae, these parasites can lead to fatal human infections.  
Until recently, P. knowlesi was considered the best model for P. vivax. Despite the relatedness 
between P. knowlesi and P. vivax, there are important phenotypic differences between them, such as 
the host blood cell preference, asexual development times (24 hours for P. knowlesi versus 48 hours 
for P. vivax), and the absence of hypnozoites (77). 
 
1.5.3 Plasmodium cynomolgi and Plasmodium vivax 
 With the recent development of a continuous in vitro culture for P. cynomolgi, this species 
presents itself as a tractable model for studying P. vivax  (50, 78). P. cynomolgi is a simian malaria 
parasite that preferentially infects Asian Old World Monkeys (e.g., Macaca fascicularis and Macaca 
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nemestrina) (79). Phylogenetic analysis of malaria parasites indicates that P. cynomolgi is the ‘sister 
taxon’ of P. vivax with >90 % of genes being conserved between them (Figure 1.3) (29, 50, 80). P. 
cynomolgi shares key biological characteristics with P. vivax, including the production of 
hypnozoites, early gametocyte formation, and invasion of Duffy blood group-positive reticulocytes 
(29, 32, 34, 81). The use of the P. cynomolgi model could allow the investigation of P. vivax biology and 
the identification of molecular markers of drug resistance. 
Like P. knowlesi, P. cynomolgi can infect human hosts. P. cynomolgi and P. vivax are almost identical 
when viewed microscopically, raising the question of whether P. cynomolgi infections have been 
misdiagnosed by microscopy as P. vivax infection for years (26, 82). The first confirmed case of 
naturally acquired human infection was identified in 2014. More recently, in 2019, another case of 
natural P. cynomolgi infection was reported (5, 83).  
 
Figure 1.3: A comparison of the genes of P. vivax (orange), P. cynomolgi (blue), and P. knowlesi 
(black). Total number of genes assigned to chromosomes listed under species name. Venn diagram 
delineates orthologous and non-orthologous genes between the three genomes, with the number of 
genes in each indicated and represented graphically by a cylinder of proportional width.  (1) 
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1.6  Plasmodium continuous in vitro culture 
The development of a continuous P. falciparum in vitro culture method proved to be a milestone in 
malaria research, enabling genetic modification of the parasite, drug screening, and other advances 
in understanding parasite biology (84-87). Adaption of other malaria parasite species to in vitro culture 
has proved more challenging, and for P. vivax, this has not yet been achieved.  
 
1.6.1  Plasmodium falciparum 
 Development of a continuous in vitro culture method for P. falciparum by Trager and Jensen 
(1976) led to advancements in understanding the parasite biology, drug discovery, and 
investigating/validating mutations associated with drug resistance (84, 88, 89).   Using the candle jar 
method, a culture was maintained for up to 2 months, retaining normal morphology, infectivity, and 
the production of merozoites (87). This methodology (with modifications including media 
components, percent haematocrit, parasitaemia, and gas mixtures) has been the basis for in vitro 
culture techniques for other Plasmodium spp.(78, 90-93).  
 
1.6.2  Plasmodium knowlesi 
 The first successful in vitro culture of P. knowlesi was achieved in 1945, the parasite being 
sustained in culture with rhesus RBCs for up to 6 erythrocytic cycles (6 days) (94). There was 
adaptation of P. knowlesi to continuous culture using macaque RBCs in 2002, which allowed for 
transfection experiments to be performed (95).  The P. knowlesi parasite was successfully adapted to 
grow in human RBCs in 2013 (96, 97). 
The first episomal transfection in P. knowlesi was carried out in 1997, demonstrating for the first 
time, that this process could be carried out in vitro using a line adapted to grow in culture with 
macaque RBCs (95, 98). More recently, the transfection of the human RBC adapted clone with an 





1.6.3 Plasmodium vivax 
 The lack of an in vitro culture method for P. vivax has meant that the knowledge base for P. 
vivax has lagged behind P. falciparum in almost every aspect (10, 56, 99-102).  Despite numerous attempts 
to culture P. vivax since 1912, the continuous culture of this species is still not feasible (52, 103-110). 
This is primarily due to P. vivax merozoite’s preference for early (CD-71 positive) reticulocytes and 
losing their ability to re-invade new host cells (52, 55, 111-113). The reason for this loss of ability to re-
invade new host cells is currently unknown. CD-71 positive reticulocytes comprise only 1-2 % of 
peripheral blood cells, mature quickly, and are primarily located in the bone marrow (54, 114, 115).  It 
was found that once P. vivax invades the reticulocyte it causes rapid maturation of the reticulocyte 
with loss of reticular matter and CD-71 within 3 hours post-invasion; presumably blocking 
subsequent non-simultaneous merozoite invasion(45).  
Parasite accumulation observed in the bone marrow suggests that P. vivax invasion may occur here, 
and not in the peripheral blood (54, 116-119). It is not understood why merozoites lose their ability to re-
invade new host cells, but it is proposed that the intrinsic characteristics of different P. vivax isolates 
and host cells are key (52, 102, 120). These gaps in knowledge, as well as the emergence of drug-resistant 
P. vivax, are hindering the development of effective treatment and control.  To overcome this 
dilemma, the use of the non-human primate infection model, P. cynomolgi, has been proposed.   
 
1.6.4  Plasmodium cynomolgi 
 Following the development of P. falciparum continuous in vitro culture, Nguyen-Dinh et al. 
(1981) and Zhou et al. (1984) successfully developed a continuous in vitro culture method for blood 
stages of P. cynomolgi (Berok and Vietnam strains respectively). Although the strains were isolated 
from different areas, both were cultured by a modified Trager-Jensen candle jar method. Additionally, 
Nguyen-Dinh et al. reported success using a continuous flow technique (87, 90, 91).   
Until recently, these culture methodologies were not investigated further.  Chua et al. (2019), revised 
and updated the methodology for the continuous in vitro culture of P. cynomolgi derived from the 
Berok strain (78). The successful propagation of the Berok K4 line was maintained for up to at least 
180 days. The parasites in these cultures were observed to retain their biological characteristics, 
transmission ability and their ability to alter RBC nanostructure and rheology (78).   
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The integrative genetic manipulation of cultured parasites has not yet been reported in P. cynomolgi; 




1.7  Malaria treatments and rising antimalarial drug resistance. 
The primary target of most antimalarial drugs is the blood-stage parasites that cause clinical malarial 
symptoms (7, 20, 27, 121).   The first-line treatment for P. falciparum is artemisinin-based combination 
therapies (ACTs), not chloroquine (CQ). This is due to the developing global prevalence of P. 
falciparum CQ resistance (122, 123).  The current first-line treatments that target blood-stage P. vivax 
infections are CQ and dihydroartemisinin/piperaquine (DHA-PIP) (64, 124-127). Currently the only Food 
and Drug Administration (FDA) approved treatment for hypnozoites is primaquine (PQ) (65, 128-130).  
While DHA-PIP and PQ are still effective P. vivax treatments, with no resistant strains being reported 
in P. vivax. CQ resistance in P. vivax has spread globally since it was first identified in Papua New 










1.7.1 Chloroquine (CQ) and resistance 
 CQ was first discovered in the 1940s and has since been used to treat, prevent and eradicate 
malaria (136, 137). It acts by accumulating in the digestive vacuole of the parasite (Figure 1.5), where it 
binds to haematin (a toxic by-product of haemoglobin proteolysis), which seems to be able to interfere 
with parasite detoxification processes, causing damage to Plasmodium spp. membranes (138-140).  
Resistance to CQ in P. falciparum was first identified in the 1950s and now occurs globally (122, 123). 
Over 30 years later, the first case of CQ resistance in P. vivax was reported (135). Since then, P. vivax 
CQ resistance has been identified in Indonesia (141, 142), Myanmar (143, 144), India (145, 146), and South 
America (147) (Figure 1.4).  The P. falciparum resistance to CQ is mediated primarily by mutant forms 
of the Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene (148).  Several variant 
residues have been identified within the pfcrt gene to confer CQ resistance.  In most cases, a lysine 
(K) residue at codon 76 (K76) is replaced with a threonine (T) (76T) (Figure 1.5)  (148-151).  This 
mutation occurs in a region of the protein that is predicted to be involved in substrate recognition. In 
P. falciparum, the K76T mutation removes the presence of a positive charge in the pfcrt substrate-
binding site to allow transport of CQ out of the digestive vacuole and away from its site of action (152-
154). It is observed that these resistant parasites accumulate substantially less CQ than CQ-sensitive 
strains in their digestive vacuole (155).  However, recently, Sá et al. (2019) noted that increased levels 
of crt expression in P. vivax were responsible for the CQ resistance seen, suggesting that the wild-
type P. vivax crt can transport CQ out of the digestive vacuole without amino acid mutations. This is 
not the case for wild-type P. falciparum, where the crt gene needs to harbour specific amino acid 
mutations to confer CQ resistance (156). While molecular markers for reduced CQ sensitivity in P. 
falciparum are relatively well characterised, the mechanisms of P. vivax CQ resistance still remain 
unknown. 
 
1.7.3 Dihydroartemisinin/piperaquine (DHA/PIP) 
 DHA acts by disrupting parasite mitochondrial function, protein transport, and the 
mitochondrial electron transport chain. PIPs exact mechanism of action is not well understood but is 
believed to be similar to that of CQ, preventing haemoglobin detoxification (125-127). Currently, the 
DHA/PIP combination therapy is a highly effective treatment for both P. vivax and uncomplicated P. 
falciparum malaria, with no evidence of DHA/PIP resistant parasites (60, 61, 131). The use of PIP as a 
monotherapy resulted in the rapid development of PIP resistant P. falciparum strains (127). Evidence 
of DHA resistance for P. falciparum is limited and observed as slowed parasite clearance (133, 157-159).  
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1.7.3 Primaquine (PQ) 
 PQs mechanism of action is not well understood, but it is believed to disrupt the mitochondrial 
electron transport chain severely. It is a prodrug that requires hydroxylation by the CYP2D6 enzyme 
within hepatocytes to become active. Mutations in this enzyme can lower drug metabolization and 
lead to recurrent malaria episodes regardless of appropriate PQ treatment. Currently, there is no 
evidence of P. vivax PQ resistance.  In cases where reoccurrence has been proposed, it is commonly 
associated with patients having lower levels of CYP2D6 activity (128-130).   
True treatment failure from PQ is hard to define due to a variety of factors: 
• PQ is typically combined with CQ therapy, and it can be difficult to distinguish between the 
efficiency of the two drugs (160) 
• Short courses of treatment are typically ineffective (161-166) 
• Different dosing levels show different treatment efficacies (23, 167-170) 
• Bodyweight and poor compliance have roles in drug efficacy (171-173) 
• The risk of PQ failure is compounded by re-infection in endemic areas (174) 
A fundamental limitation for the use of PQ as a major antimalarial is the dose-dependent haemolytic 
anaemia it causes in glucose-6-phosphate dehydrogenase (G6PD) deficient patients (175-177). Although 
PQ is an important treatment for P. vivax malaria, it is underused due to a lack of G6PD deficiency 
testing and concerns about toxicity. There is thus a need for the development of alternative ‘radical 
cure’ treatments such as PQ. It should be noted that another 8-amino-quinolone known as tafenoquine 
(KrintafelTM) was approved for use in 2018. While Tafenoquine has a significantly longer plasma 
half-life thus improving compliance, it is also contraindicated in patients with an abnormal G6PD 
phenotype. 
 
1.7.4 Atovaquone (ATO) and resistance 
 MalaroneTM was introduced for prophylaxis and treatment of P. falciparum in 1996 and has 
more recently been used to treat CQ resistant P. vivax infections (178, 179). It is a combination therapy 
comprised of atovaquone (ATO) and the prodrug proguanil (PG), which is converted to its active 
form cycloguanil by the liver enzyme CYP2C19 (180, 181).   
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ATO is a hydroxynaphthoquinone that inhibits the mitochondrial electron transport chain at 
cytochrome b (cytb) by targeting the ubiquinol oxidation pocket in the bc1 complex (Figure 1.5).  This 
results in a loss of mitochondrial function and parasite death (64, 180, 182-184).  It is active against both 
blood-stage parasites and liver schizonts; however, it is not believed to be active against hypnozoites 
(185-187). PG has no direct effects on the parasite mitochondrial electron transport chain but acts 
synergistically to lower the concentration of ATO required to cause the collapse of the mitochondrial 
membrane potential (180, 188).  
The use of ATO as monotherapy in P. falciparum treatment has resulted in rapid selection for drug 
resistance in P. falciparum (183, 185, 189).  However, the use of malarone against both ATO-sensitive and 
ATO-resistant P. falciparum isolates resulted in prompt clinical responses and cure rates of nearly 
100 % (181, 183). 
Thanks to the development of continuous in vitro culture for P. falciparum, mutations at amino acid 
268 of the cytb gene have been validated as a cause of ATO resistance in P. falciparum, with the 
Y268S being the most common mutation reported (190-194).  Hydrophobic contacts stabilise the 
interactions between ATO and cytb. The Y268S mutation causes ATO’s contact to be significantly 
reduced, forcing ATO to bind at distant locations from its active site (195, 196).  Currently, there is no 
evidence of this mutation in P. vivax strains, where ATO/malarone treatment has failed (187, 197). A 
lack of in vitro culture techniques limits the ability to investigate and validate this mutation (and many 
others) in P. vivax.  However, with the development of our P. cynomolgi model coupled with the 
ability to culture P. cynomolgi in vitro efficiently, we open the doors to the identification and 








Figure 1.5: Mode of action for A) Atovaquone (ATO) and B) Chloroquine (CQ). Mutations of cytb (Y268S) and crt (K76T) genes shown causing 





1.8  Drug resistance markers in Plasmodium falciparum  
The common P. falciparum drug resistance markers are shown inTable 1.1. 
Table 1.1: Drug resistance markers in P. falciparum   
Gene Normal gene function 
Conferred drug 
resistance 
Common Mutations that 
confer resistance 
Chloroquine resistance 
transporter (crt) (200) 
Channel or transporter in the Plasmodium spp. digestive vacuole and 
part of the drug-metabolite transporter superfamily 
Chloroquine 
K76T (AAA à AcA) 
N75E (AAT à gAa) 
C72S (TGT à aGT) 
M74I (TGT à aGT) 
Multidrug resistance 
gene 1 (mdr1) (200, 201) 
Produces P-glycoprotein homologue 1 which is located in the 
digestive vacuole membrane of the parasite. Its role is proposed as an 
importer of solutes into the digestive vacuole. 
Chloroquine 
N86Y (TGA à TGt) 
D1246Y (GAG à GAt) 
Dihydrofolate reductase 
gene (dhfr) (202-204) 
Enzyme that catalyses the NADPH-dependent reduction of 
dihydrofolate to tetrahydrofolate. This is essential for the de novo 
synthesis of purines and certain amino acids, making dhfr essential 
for rapid growth. 
Pyrimethamine 
S108N (TCG à aac) 
N51I (AAC à AtC) 





(K13 propeller)  (205, 206) 
Belongs to the kelch superfamily of proteins, whose propeller 
domain harbours multiple protein-protein interaction sites and 
mediates diverse cellular functions. 
Artemisinins 
R539T (AGA à AcA) 
C580Y (TGT à TaT) 
Y493H (TAC à cAC) 
I543T (ATT à AcT) 





1.9  Genetic manipulation of Plasmodium  
With the public release of the lab cultured P. falciparum genome in 2002, genomic research on 
malaria parasites advanced rapidly. The haploid genome is 22.8 megabases (Mb) and contains ~5,300 
genes encoded on 14 chromosomes. Of the Plasmodium species, P. falciparum is the most AT rich 
genome at 80.6 %, increasing to almost 90 % in introns and intergenic regions. A high AT content is 
characteristic of the Plasmodium spp. with the AT content of P. vivax and P. cynomolgi being 60.3 
% and 59.6 % respectively (50, 73, 207).   
The molecular characterisation of P. falciparum and other Plasmodium spp. allowed for genome-
wide association studies – an approach used to associate specific genetic variations with particular 
diseases. This method involves scanning the genomes from many different parasites and looking for 
genetic markers that can be used to predict the presence of certain mutations. These studies were 
crucial in identifying specific genes and single nucleotide polymorphisms (SNPs) associated with 
increased antimalarial resistance.  However, in order to phenotypically confirm the role of these genes 
and SNPs in drug resistant parasites, we need to be able to genetically modify wild type parasites (by 
gene knock out, the introduction of transgenes, or gene mutation).  
The repair mechanism – homologous recombination – relies upon rare random double-stranded 
breaks (DSBs) occurring close to the target site. It is understandable that gene disruption using this 
technique has low efficiency, taking one to three months of continuous culture before integration 
would occur. Contemporary methods such as Zinc finger nucleases (ZFNs), Transcription activator-
like effector nucleases (TALENs), and CRISPR (clustered regularly interspaced short palindromic 
repeat)-Cas (CRISPR associated proteins) mediated gene editing use site-specific nucleases to cleave 
precisely, allowing for homology directed repair (HDR) using a supplied template.  
 
1.9.1 Plasmodium repair mechanisms  
A DSB in the deoxyribonucleic acid (DNA) of a cell is fatal if it is not repaired. Organisms 
can employ non-homologous end-joining (NHEJ) or homology directed repair (HDR) as a 
mechanism of DNA repair (208).  
To our knowledge, bioinformatic analyses show Plasmodium spp. does not carry the genes known to 
encode enzymes required for NHEJ (207).  A lack of NHEJ repair can be beneficial for reverse 
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genomics as it results in fewer unintended or off-target effects, as cleavage at undesired loci cannot 
be easily repaired. The error-prone nature of NHEJ is a valuable tool for introducing random point 
mutations at certain site following cleavage. However, as NHEJ is not available in Plasmodium spp. 
it is not available for malaria research.  Instead, repair relies predominantly on HDR, which utilises 
a template (sister chromatid or a donor plasmid) to guide highly accurate repair (208, 209).  
There is some evidence for possible alternative end-joining mechanisms (such as microhomology-
mediated end joining and single-strand annealing) occurring in P. falciparum 3D7, however this is 
not a major mechanism of DNA repair. This mechanism includes resection of single-strand overhangs 
and insertion of short stretches of synthesised nucleotides at the site of the break (210, 211).  
HDR can be (and has been) exploited to allow manipulation of the P. falciparum, P. vivax and, now, 
the P. cynomolgi genome, by introducing a double-stranded break at a site of interest and supplying 
a repair template to drive HDR (208, 212-218).  
 
1.9.2 Development of transfection technologies for Plasmodium parasites 
Advances in techniques to genetically modify  Plasmodium spp. led to the development of transient 
and stable transfection systems to express reporter genes, and provide the ability for knock out, 
knock-down or gene replacement through conventional recombination or through more directed 
genome-editing approaches (such as ZFN and CRISPR-cas systems) (219).  
Transient transfection of Plasmodium spp. was first reported in 1993, where there was successful 
introduction and expression of a luciferase reporter gene in the avian malaria species Plasmodium 
gallinaceum (220). Shortly thereafter, stable transfection systems for P. falciparum and Plasmodium 
berghei were developed, allowing long term expression of genes which were able to integrate into 
the parasite genome.  
The first transfection of primate Malaria occurred in 1997, where Van der Wel et al were able to 
stably transfect P. knowlesi to produce pyrimethamine-resistant parasites (221). Two years later, 
Kochen et al (1999) were able to also stably transfect another primate malaria, P. cynomolgi, to 
produce pyrimethamine resistance parasites (216).  Although these transient and stable transfection 
systems have been described for P. vivax, without there being a robust in vitro culture method 
available it is not possible to resourcefully study P.vivax’s biology using genetic technologies (215, 
222).  
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Techniques for the genetic manipulation of Plasmodium spp. are currently being developed further, 
with great interest from the field of malaria research. These techniques have the potential to, amongst 
other things, identify and validate mutations associated with drug resistance.  
ZFNs, and CRISPR-Cas systems, which cleave DNA, have been used to introduce mutations into the 
P. falciparum genome (208, 212-214). Before the use of ZFNs and CRISPR-Cas, genetic manipulation of 
Plasmodium spp. relied on recombination strategies, which would often take months to produce 
mutants, with relatively poor yield (212, 223, 224).  
 
1.9.3 Genetic manipulation of Plasmodium falciparum 
 Transfections of P. falciparum have traditionally been performed using electroporation, 
targeting ring stage infected erythrocytes with a Bio-rad gene pulser. This technique was first 
described by Wu et al (1995) and utilises a high voltage/low capacitance (short pulse duration) electric 
pulse (225). However, some cells (especially primary cells) are very easily killed and thus electroporate 
poorly at high voltages. This method has since been replaced with more efficient transfection of ring 
stage parasites at low voltage/high capacitance (long pulse duration) electric pulse described by 
Fidock et al (1997) (226). Even with this improvement, transfection efficiencies of P. falciparum are 
still low, being reported between 10-2 and 10-5 for transient transfections, and 10-6 for stable 
transfections (227).  
In 2012, Straimer et al. used ZFNs to introduce the K76I mutation into the P. falciparum chloroquine 
resistance transporter (pfcrt) gene, conferring CQ resistance (212). Although ZFNs are more efficient 
than previous techniques, the design process is laborious and difficult.   
An alternative, highly efficient genome editing technique is CRISPR-Cas (213). Cas proteins can very 
accurately introduce specific double-stranded breaks in a target gene.  Supplying a donor template on 
a plasmid allows the exploitation of host HDR to introduce the desired mutation (208, 209, 213).  
Two studies used CRISPR-Cas to edit the P. falciparum genome in 2014 (213, 214).  Ghorbal et al. 
(2014) used CRISPR-Cas to introduce the C580Y mutation into the P. falciparum kelch propeller 
domain (K13-propeller), conferring artemisinin resistance (213, 228). Wagner et al. (2014) used 
CRISPR-cas to create targeted disruptions in the knob associated histidine rich protein (kahrp) and 
erythrocyte binding antigen (eba) genes (214).  
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The use of reverse genetics in P. falciparum has now become almost standard practice in laboratories 
exploring the molecular mechanisms behind the biology of this important human pathogen. 
Unfortunately, the molecular manipulation of P. vivax has been largely neglected due to a range of 
practical and intrinsic biological characteristics of this species.  
  
1.9.4 Genetic manipulation of Plasmodium vivax 
 The HDR mechanism has also been exploited in one study to modify the P. vivax genome 
(215). Before this work, only a transient transfection with a luciferase reporter had been reported for P. 
vivax (229).  In 2014, Moraes Barros et al. used ZFNs to successfully produce a pyrimethamine resistant 
P. vivax population by introducing four mutations (F57L, S58R, T61M, and S117T) into the P. vivax 
dihydrofolate reductase (dhfr) gene (215). The lack of an in vitro culture method meant that in vivo 
cultivation of parasites in Saimiri boliviensis monkeys was used (215, 230, 231). Although the use of 
monkeys for such experiments is expensive, in the absence of a routine in vitro culture, genetic 
manipulation in P. vivax parasites will continue to depend on costly non-human primates.  
 
1.9.5 Genetic manipulation of Plasmodium cynomolgi 
 While there has been episomal expression of heterologous constructs and fluorescent markers, 
there is currently no evidence of integrative genetic manipulation in P. cynomolgi (216-218). Kochen et 
al. (1999) successfully produced a pyrimethamine resistant P. cynomolgi population by expressing a 
mutagenized Toxoplasma gondii dihydrofolate reductase-thymidylate synthase (dhfr-ts) gene 
episomally.  This was the first evidence that blood-stage P. cynomolgi was modifiable by transfection 
(216). Vooberg-van der Wel et al. (2013) were able to analyse liver stage development of P. cynomolgi 
by producing transgenic parasites that episomally expressed fluorescent markers. By using a P. 
cynomolgi centromere, episomes containing fluorescent expression markers were able to be stably 
passed on during in vivo propagation (217, 232, 233). 
 
1.9.6 Difficulties associated Plasmodium transfection 
Although there has been promising development of molecular tools for the editing of  Plasmodium 
spp. genomes, there are a number of key issues that still need to be resolved. First, genes that are 
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essential to parasite survival are understandably difficult to study using gene disruption methods. 
Second, transfection efficiencies are still not at a level to permit saturation genetic screens (the ability 
to identify genes responsible for a particular phenotype). Thirdly, there needs to be development of 
appropriate functional assays to define transgenic parasite phenotypes, and more precisely determine 
the role ‘genes of interest’ play in molecular pathways. 
Plasmodium spp. transfected by electroporation with plasmid DNA, initially replicates episomally, 
and can enable expression of transgenes. By contrast, to introduce, replace, mutate or knockout a 
particular gene, a homologous targeting sequence(s) must be incorporated into the plasmid repair 
template to drive integration into the host genome. The selection of parasites with stably integrated 
constructs is complicated and time consuming (219, 234). Many Plasmodium spp. can be transfected 
using electroporation of plasmid DNA. However, even in P. falciparum (where this technology is 
best understood), this method still has sub-optimal efficiencies. In P. falciparum the transfection 
efficiency has been recorded to be between 10-2 and 10-5 for stable transfections (235). This inefficiency 
is hardly surprising considering that this exogenous DNA needs to cross three membranes to enter 
the parasite cytoplasm (the erythrocyte membrane, the parasitophorous vascular membrane, and the 
parasite plasma membrane). 
The suboptimal transfection efficiencies associated with Plasmodium spp. hinders not only the pace 
of progress (due to the time taken to obtain transfectants), but makes it nearly impossible to select 
transgenic parasites that have delayed growth. One development aimed to target this is the use of 
protease inhibitors that prevent schizont rupture but still allow merozoites to mature during the in 
vitro culture period (236). Using these protease inhibitors, there is enrichment of parasites at the late 
schizont stage. Once protease inhibitors’ pressure is released, schizonts rapidly rupture to release their 
merozoites, which is the targeted stage for the Amaxa 4D Nucleofactor.  
Another contributor limiting the progress of genetic manipulation of Plasmodium  spp. is a lack of 
robust positive selectable markers. This prevents performing consecutive genetic manipulations on 
the same parasite. Although six selectable markers are now available for P. falciparum, human-dhfr 
(conferring resistance to the drug WR99210) is predominantly used because of its robustness. The 
introduction of negative selection has helped overcome this issue, as it allows recycling of the positive 
selectable marker.  
Transfection research in P berghei shows an increased transfection efficiency using the Amaxa 4D 
Nucleofactor device compared to other electroporation devices which target the late schizont 
(specifically, the merozoite stage) (236). Of particular note, the use of the Amaxa 4D Nucleofactor for 
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P. falciparum transfection resulted in detection of stably transfected parasites as early as 8 days post 
transfection (213).  
Although there is still plenty of room for further optimisation, these advancements are already 
allowing important understanding of Plasmodium spp. invasion, development, replication, 
transmission and investigating molecular markers associated with drug resistance. 
  
 26 
1.10 Research aims 
This project aimed to exploit P. cynomolgi in vitro culture as a model to investigate the molecular 
mechanisms of P. vivax drug resistance and erythrocyte invasion.  
To investigate the molecular basis for antimalarial resistance in P. vivax requires the development of 
CRISPR plasmids expressing the mutations known to be associated with drug resistance in P. 
falciparum. It was hypothesised that these mutations, once integrated into orthologous P. cynomolgi 
genes, would confer drug resistance, as seen in P. falciparum.  
The identification of potential drug resistance mutations in P. vivax is essential to advance the 
understanding of how each Plasmodium spp. develops drug resistance. The identification and 
validation of putative drug resistance mutations in Plasmodium spp., will inform research and 
policymaking decisions targeting drug resistant vivax malaria. 
Finally, to investigate key P. vivax red cell invasion ligands using GFP tagged reporter proteins.  
These fluorescent P. cynomolgi parasites would be used to model the invasion biology of P. vivax, 
and further our understanding of the trafficking and presentation of proteins involved in erythrocyte 























2.1 Recipes for media and solutions 
2.1.1 Complete Plasmodium cynomolgi media 
For ~500 mL: 
500 mL RPMI 1640 with L-glutamine and 25 millimolar (mM) HEPES (Cat. No. 22400089, 
Gibco) 
900 µL of 200 µM hypoxanthine (see 2.1.7) 
400 µL penicillin (31.25 mg/mL) (see 2.1.9) 
250 µL cefquinome (1 mg/mL) (see 2.1.8) 
50 mL heat inactivated M. fasicularris serum (see 2.2.4) 
50 mL heat inactivated foetal bovine serum (FBS) (Cat. No. MORFBSFNZ, In Vitro 
Technologies) 
2 g D-glucose (Cat. No. BSPGL903.500, LabServ)  
Filter sterilised over 0.22 µm filter (Cat No. 760502, Ahlstrom Munksjo) 
Aliquot media into 50 mL volumes and parafilm wrap 
Stored in 4 ºC and used within 1 month. 
 
2.1.2 Plasmodium cynomolgi culture media 
For ~500 mL: 
500 mL RPMI 1640 with L-glutamine and 25 mM HEPES (Cat. No. 22400089, Gibco) 
2 g D-glucose (Cat. No. BSPGL903.500, LabServ)  
2.5 g Albumax II (Cat. No. 11021-045, Life Technologies)  
Filter sterilised over 0.22 µm filter 
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900 µL of 200 µM hypoxanthine (see 2.1.7) 
400 µL penicillin (see 2.1.9) 
250 µL cefquinome (see 2.1.8) 
50 mL heat inactivated Horse Serum (Cat. No. 26050-088, Gibco) 
Aliquot into 50 mL volumes and parafilm wrapped 
Stored in 4 ºC and used within 1 month. 
 
2.1.3 Plasmodium cynomolgi wash media 
For ~500 mL: 
500 mL RPMI 1640 with L-glutamine and 25 mM HEPES (Cat. No. 22400089, Gibco) 
400 µL penicillin (see 2.1.9) 
250 µL cefquinome (see 2.1.8) 
Aliquot into 50 mL volumes 
Stored in 4 ºC and used within 1 month. 
 
2.1.4 Plasmodium cynomolgi compound 2 media 
For ~50 mL: 
50 mL RPMI 1640 with L-glutamine and 25 mM HEPES (Cat. No. 22400089, Gibco) 
50 µL Compound 2 (final concentration of 1 µM) (Gifted by Michael Blackman, The Francis 
Crick Institute) 
Stored in 4 ºC and used within 1 month. 
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2.1.5 Plasmodium cynomolgi WR99210 drug media 
For ~50 mL: 
50 mL Plasmodium cynomolgi culture media (See 2.1.2) 
50 µL WR99210 (2.5 µM) (see 2.1.11) 
Stored in 4 ºC and used within 1 month. 
 
2.1.6 Sodium hydroxide (NaOH) 
For 250 mL: 
 10 g NaOH (Cat No. 04251000, Scharlau) 
 Dissolved in 250 mL MilliQ water 
 Autoclave 
 Store at 4 ºC  
 Use within 1 month 
 
2.1.7 Hypoxanthine 200mM 
For 150 mL: 
 4.08 g hypoxanthine (Cat. No. A11481, Alfa Aesar) 
 Dissolved in 150 mL of sterile MilliQ water 
 Filter sterilise over 0.22 µm filter  
 Aliquot into 1 mL volumes 
 Store at -20 ºC until use 
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2.1.8 Cefquinome (1 mg/mL) 
For 16 mL: 
 0.016 g of cefquinome sulphate (Cat No. 32472-100MG, Sigma) 
 Dissolved in 16 mL of sterile MilliQ water 
Filter sterilise over 0.22 µm filter (Cat No. 760502, Ahlstrom Munksjo) 
 Aliquot into 4 mL volumes  
 Store at -20 ºC until use 
 
2.1.9 Penicillin (31.25 mg/mL) 
For 16 mL: 
 0.5 g of penicillin G potassium salt (Cat No. P7794-10MU, Sigma) 
 Dissolved in 16 mL of sterile MilliQ water 
 Filter sterilise over 0.22 µm filter (Cat No. 760502, Ahlstrom Munksjo) 
 Aliquot into 4 mL volumes  
 Store at -20 ºC until use 
 
2.1.10 WR99210 (0.25 mM) 
For ~500 µL: 
 5 µL of WR99210 (10 mg/mL) (Gifted by Fiddock Lab, Columbia University)  
 Dilute in 495 µL of sterile MilliQ water 
 Store at -20 ºC until use 
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2.1.11 WR99210 (2.5 µM) 
For 500 µL: 
 5 µL of WR99210 (0.25 mM) (see 2.1.10) 
 Dilute in 495 µL of sterile MilliQ water 
 Store at -20 ºC until use 
For 20 mL: 
 200 µL of WR99210 (0.25 mM) (see 2.1.10) 
Dilute in 19.8 mL of sterile MilliQ water 
Aliquot into 55 µL volumes 
Store at -20 ºC until use 
 
2.1.12 Ampicillin (100 mg/mL) 
For 10 mL: 
 1 g of ampicillin sodium Salt (Cat. No. A0839, Applichem) 
 Dissolved in 10 mL of sterile MilliQ water 
 Aliquot into 250 µL volumes 
 Store at -20 ºC until use 
 
2.1.13 Dulbecco’s Phosphate Buffer Solution (PBS) 
For 1L: 
 1 Sachet of Dulbecco’s PBS (Cat. No. 21600-010, Gibco) 
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 Dissolved in 1 L of MilliQ water 
 pH 7.2 
 Autoclave  
 Store at 4 ºC  
 Use within 1 month 
  
2.1.14 10 % Giemsa working solution 
9 volumes of PBS (see 2.1.13) 
1 volume of Giemsa (Cat. No. VWRC350865P, VWR)  
Always prepared fresh before use 
 
2.1.15 5 % (w/v) Sorbitol solution 
For 500 mL: 
25 g sorbitol (Cat. No. AC132735000, ThermoFisher)  
Dissolved in 500 mL of MilliQ water  
Autoclave 
Store in 4 ºC  





2.1.16 140 mM Guanidine Hydrochloride (GuHCl) solution 
For ~100 mL: 
 1.374 g GuHCl (Cat. No. A13543, Alfa Aesar) 
 Dissolved in 100 mL of MilliQ water 
1.055 mL HEPES (1 M) (Cat. No. 15630-080, Gibco) 
Autoclave 
Store are 4 ºC 
Use within 1 month 
 
2.1.17 27.6 % (w/v) Nycodenz  
For ~250 mL: 
 69 g Nycodenz (Cat. No. 1002424, Alere Technologies) 
 Dissolved in 250 mL of MilliQ water 
2.5 mL HEPES (1 M) (Cat. No. 15630-080, Gibco) 
Autoclave 
Store at 4 ºC 
Use within 1 month 
 
2.1.18 55 % Nycondenz solution 
For 100 mL: 
 45 mL of RPMI 1640 with L-glutamine and 25 mM HEPES (Cat. No. 22400089, Gibco) 
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 55 mL of 27.6 % Nycodenz solution (See 2.1.17) 
Store at 4 ºC 
Use within 1 month 
 
2.1.19 12 % (w/v) Sodium Chloride (NaCl) 
For 250 mL: 
30 g of NaCl (Cat. No. 7647-14-5, Merck)  
Dissolved in 250 mL of MilliQ water 
Autoclave 
Store at 4 ºC  
Use within 1 month 
 
2.1.20 1.6 % (w/v) Sodium Chloride (NaCl) 
For 250 mL: 
4 g of NaCl (Cat. No. 7647-14-5, Merck)  
Dissolved in 250 mL of MilliQ water 
Autoclave 
Store at 4 ºC  




2.1.21 0.9 % (w/v) Sodium Chloride (NaCl) 
For 250 mL: 
2.25 g of NaCl (Cat. No. 7647-14-5, Merck)  
Dissolved in 250 mL of MilliQ water 
Autoclave 
Store at 4 ºC  
Use within 1 month 
 
2.1.22 Luria-Bertani (LB) broth  
For 500 mL: 
12.5 g LB broth (Cat. No. 244620, BD Bioscience)  
Dissolved in 500 mL of MilliQ water  
Autoclave  
Store at 4 ºC  
Use within 1 month 
 
2.1.23 Luria-Bertani (LB) broth with ampicillin 
For ~500 mL: 
12.5 g LB broth (Cat. No. 244620, BD Bioscience)  
Dissolved in 500 mL of MilliQ water  
Autoclave  
 37 
500 µL ampicillin (100 mg/µL) (see 2.1.12) 
Store at 4 ºC  
Use within 1 month 
 
2.1.24 Super optimal broth with catabolite repression (SOC) media 
For 500 mL: 
10 g BactoTM Tryptone (Cat. No. 211705, BD Bioscience) 
2.5 g BactoTM Yeast extract (Cat. No. 212750, BD Bioscience) 
0.293 g sodium chloride (NaCl) (Cat. No. 7647-14-5, Merck) 
0.093 g potassium chloride (KCl) (Cat. No. P9541-500G, Sigma-Aldrich) 
Dissolved in 490 mL of MilliQ water  
Autoclave  
Dissolve 1.0165 g of magnesium chloride (MgCl2) (Cat. No. M866-100G, Sigma-Aldrich) in 
4.460 mL of sterile MilliQ water 
Dissolve 1.23 g of magnesium sulphate (MgSO4) (Cat. No. B10151, BDH inc) in 4.37 mL of 
sterile MilliQ water 
Dissolve 1.8016 g of D-Glucose (Cat. No. BSPGL903.500, LabServ) in 10 mL of sterile 
MilliQ water 
Filter sterilise MgCl2, MgSO4, and D-Glucose solutions over a 0.22 µm filter 
Store at 4 ºC  
Use within 1 month 
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2.1.25 Luria-Bertani (LB) agar plates  
For 250 mL: 
10 g LB agar (Cat. No. GM1151-500G, HIMEDIA)  
Dissolved in 250 mL of MilliQ water  
Autoclaved 
Pour plates 
Store plates in 4 ºC  
Use within 1 month 
 
2.1.26 Luria-Bertani (LB) agar plates with ampicillin 
For ~250 mL: 
10 g LB agar (Cat. No. GM1151-500G, HIMEDIA)  
Dissolved in 250 mL of MilliQ water  
Autoclaved 
250 µL of ampicillin (100 mg/mL) (See 2.1.12) 
Pour plates 
Store plates in 4 ºC  





2.1.27 Luria-Bertani (LB) agar plates with X-gal, IPTG, and ampicillin 
For ~250 mL: 
10 g LB agar (Cat. No. GM1151-500G, HIMEDIA)  
Dissolved in 250 mL of MilliQ water  
Autoclaved 
1.25 mL IPTG (0.5 mM) (Cat. No. APPA4773,0005, LabSupply) 
400 µL X-Gal (80 µg/mL) (Cat. No. APPA4978,0001, LabSupply) 
500 µL of ampicillin (50 ng/µL) (Cat. No. APPA0839,0025, Life Science) 
Pour plates 
Store plates in 4 ºC  
Use within 1 month  
 
2.1.28 75mM CaCl2/10nM PIPES/15 % glycerol solution 
For ~200 mL: 
2.205 g calcium chloride dihydrate (CaCl2.2H2O) (Cat. No. MER1023780500, LabSupply) 
0.6048 g PIPES (Cat. No. P6757, Sigma) 
Made to 200 mL with sterile MilliQ water  
30 mL of glycerol (Cat. No. G9012-500ML, Sigma) 
Add sodium hydroxide (NaOH) (Cat. No. MER1091411000, LabSupply) until PIPES is fully 
dissolved using stirrer 
Add hydrochloric acid (HCl) until pH reaches 7 
Filter sterilised over 0.22 µm filter  
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Store at 4 ºC until use.  
 
2.1.29 1x TAE Buffer 
For 2 L: 
40 mL TAE buffer (50x) (Cat. No. APPA1691, Lab Supply) 
Dilute with 1960 mL of MilliQ water 
Store at RT  
 
2.1.30 1 % agarose gel 
For a ~50 mL: 
0.5 g agarose (Cat. No. APPA2114, Lab Supply) 
Dissolved in 50 mL 1x TAE buffer (see 2.6.29) 
5 µL of SyberSafe (Cat. No. S33102, Invitrogen) 
Pour into gel mould and let set  
For a ~100 mL: 
1 g agarose (Cat. No. APPA2114, Lab Supply) 
Dissolved in 100 mL 1x TAE buffer (see 2.6.29) 
Add 10 µL of SyberSafe (Cat. No. S33102, Invitrogen) 




2.1.31 1 kb plus DNA ladders 
For 500 µL: 
400 µL MilliQ water 
50 µL purple loading dye (6x) (Cat. No. B7025S, NEB) 
50 µL 1 kb+ DNA ladder (Cat. No. N0550L, NEB) 
 
2.1.32 Colony PCR Mastermix 
For 10 mL: 
 2 mL ammonium sulphate ((NH4)2SO4) buffer (Cat. No. 13701-500G, ECP LabChem) 
 1.6 mL magnesium chloride (MgCl2) (Cat. No. M8266-100G, Sigma-Aldrich) 
 400 µL Taq polymerase (Cat. No. EP0402, Thermo Scientific) 
 400 µL dNTPs (Cat. No N0447S, GeneSearch) 
 Dilute in 5.9 mL MilliQ water 
 Filter sterilised over 0.22 µm filter  
 Aliquot into 500 µL volumes 
Store at -20 ºC until use 
 
2.1.33 Inoue transformation buffer 
For 200 mL: 
0.44 g calcium chloride dihydrate (CaCl2.2H2O) (15 mM) (Cat. No. 223506, Sigma-Aldrich) 
3.7 g potassium chloride (KCl) (250 mM) (Cat. No. P9541-500G, Sigma-Aldrich) 
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0.48 g HEPES (10 mM) (Cat. No. 1069,0100, PanReac AppliChem) 
Dissolve in 200 mL of Milli-Q water 
Add potassium hydroxide (KOH) until pH reaches 6.7  
2.18 g manganese(II) chloride tetrahydrate (MnCl2.4H2O) (55 mM) (Cat. No. 25222.233, 
VWR) 
Filter sterilised over 0.22 µm filter  
Store at 4 ºC until use.  
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2.2 Continuous in vitro culture of Plasmodium cynomolgi Berok 
erythrocytic stages 
 
Figure 2.1: Flow diagram showing an overview of the P. cynomolgi Berok in vitro culture process (student 




2.2.1  Ethical committees and animal welfare 
Macaca fascicularis (cynomolgous monkey) blood and serum were imported from the 
Monash Animal Research Platform, Gippsland, Australia (Monash University). Collection of blood 
followed Monash Animal Research Platform’s standard operating procedures. Animals were housed 
in accordance with the Australian Code of Practice, and the Laboratory animals Code of Practice. 
Import permits were approved by the Convention on International Trade in Endangered Species of 
Wild Fauna and Flora, and import declarations were approved by the Ministry of Primary Industries, 
New Zealand. Genetic manipulation of P. cynomolgi was approved by the University of Otago 
Institutional Biological Safety Committee, and research on Plasmodium in New Zealand was 
undertaken following consultation with The Ngāi Tahu Research Consultation Committee.  
 
2.2.2  Plasmodium strains  
Plasmodium strain used in culture are shown in Table 2.1. 
Table 2.1: Plasmodium strain used for continuous in vitro culture. 
Strain Source 
Plasmodium cynomolgi Berok K4A7 Professor Dennis E. Kyle (University of Georgia) 
 
2.2.3 Macaque naïve blood extraction and preparation 
 Naïve RBCs were obtained from M. fascicularis maintained at Monash Animal Research 
Platform (see 2.2.1). Whole blood was collected by venipuncture into lithium heparin vacutainers. 
To remove leukocytes, the blood collected was adjusted to 50 % haematocrit with RPMI 1640 with 
L-glutamine and 25mM HEPES (Cat. No. 22400089, Gibco) and filtered through pre-equilibrated 
non-woven filters (Antoshin). To prepare naïve M. fascicularis RBCs for culture, RPMI 1640 with 
L-glutamine and 25mM HEPES (Cat. No. 22400089, Gibco) was used to wash RBCs three times. 
The naïve M. fascicularis RBCs were cryopreserved (see 2.2.5) and stored in liquid nitrogen until 
use.   
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2.2.4 Macaque naïve serum extraction and preparation 
Serum was obtained from M. fascicularis maintained at Monash Animal Research Platform 
(see 2.2.1). Whole blood was collected by venipuncture into clot activator vacutainers and allowed 
to clot in a vertical position. The M. fascicularis serum supernatant was collected and heat-inactivated 
for 1 hour at 56 ºC and stored at -20 ºC until use.  
 
2.2.5 Cryopreservation of Plasmodium cynomolgi erythrocytic stages 
To cryopreserve P. cynomolgi parasite culture, sorbitol synchronised (see 2.2.9) cultures (at 
least 1 % ring stage) were pelleted by centrifugation at 1800 rpm for 5 minutes at room temperature. 
Glycerolyte 57 (Cat. No. P65FR4A7831, Pharmaco) was added, at a volume of 0.33x the RBC pellet, 
dropwise at 4 sec intervals while gently mixing. Blood cells were incubated for 5 minutes at room 
temperature. Glycerolyte 57 was added, at a volume of 1.33x the RBC pellet, dropwise at 2 sec 
intervals while gently mixing. Depending on volume, cells are aliquoted into 1.8 mL cryofreeze tubes 
and stored overnight in the Mr. Frosty TM freezing container (Cat. No. 5100-0001, ThermoFisher 
Scientific) at -80 ºC before they were permanently stored in Liquid nitrogen tank or until use.  
 
2.2.6 Thawing of frozen parasite stock and M. fascicularis naïve RBCs 
 The P. cynomolgi parasite in vitro culture was started from a 1 mL cryopreserved sample. 
Frozen samples were thawed using the sodium chloride (NaCl) method (237). In brief, 12 % NaCl (see 
2.1.19) was added, at a volume of 0.1x the RBC pellet, dropwise at 10 sec intervals while gently 
mixing. Cells were incubated for 5 minutes at room temperature. 1.6 % NaCl (see 2.1.20) was added, 
at a volume of 10x the RBC pellet, dropwise at 4 sec intervals while gently mixing. The cells were 
centrifuged at 1800 rpm for 5 minutes (Cat No. THR75004515, ThermoFisher) at room temperature 
and supernatant was removed. 0.9 % NaCl (see 2.1.21) was added, at a volume of 10x the RBC pellet, 
dropwise at 10 sec intervals while gently mixing. The cells were centrifuge at 1800 rpm for 5 minutes 
at room temperature and supernatant was removed.  RBCs were resuspended in RPMI 1640 with L-
glutamine and 25mM HEPES (Cat. No. 22400089, Gibco) and stored at 4 ºC until use. Thawed 
parasite cultures were resuspended to 3 % haematocrit in P. cynomolgi culture media (see 2.1.2). 
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2.2.7 Routine in vitro P. cynomolgi culture  
P. cynomolgi cultures of varying volumes were maintained at ~3 % haematocrit with naïve 
M. fascicularis RBCs in 5 mL culture wells (Cat No. CLS3513, MERCK) or cell culture flasks (Cat. 
No. GR660160, Mediray). Cultures were kept gassed with trimix gas (5 % carbon dioxide, 5 % 
oxygen, 90 % nitrogen) and incubated at 37 ºC. Daily Giemsa-stained thin blood smears were 
performed to monitor parasitaemia by microscopy (see 2.1.14), and parasitaemia adjusted between 1-
5 %. The P. cynomolgi culture media (see 2.1.2) was changed every other day.  
 
2.2.8 Determination of parasitemia via light microscopy of Giemsa-stained smears 
Thin blood smears were fixed with 100 % methanol (Cat. No. BSPML868.2.5-PL, LabServ) 
and dried before being stained with 10 % giemsa stain (See 2.1.14) for 10 minutes then rinsed. Thick 
blood smears were dried completely before being stained with 10 % giemsa stain (See 2.1.14) for 10 
minutes then rinsed. Parasitemia was the percentage of RBCs infected by P. cynomolgi. Parasitemia 
was determined using the Olympus BX43 light microscope (Olympus) with the 100x magnification 
with oil immersion lens. 
 
2.2.9  P. cynomolgi ring stage synchronisation using 5 % sorbitol 
P. cynomolgi cultures (at >1 % ring stage) were centrifuged at 1800 rpm for 5 minutes at room 
temperature and the supernatant was removed. The RBC pellet was resuspended in 5 % sorbitol (see 
2.1.15) to give a final haematocrit of  >50 %. Cells were incubated for 15 minutes at 37 ºC. Cells 
were centrifuged at 1800 rpm for 5 minutes at room temperature and supernatant was removed. The 
RBC pellet was washed three times with PBS (see 2.1.13) then resuspended in P. cynomolgi culture 
media (see 2.1.2).  
 
2.2.10  P. cynomolgi ring stage synchronisation using 140 mM Guanidine Hydrochloride 
(GuHCl) 
P. cynomolgi cultures (at >1 % ring stage) were centrifuged at 1800 rpm for 5 minutes at room 
temperature and supernatant was removed. The RBC pellet was resuspended in 140 mM guanidine 
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hydrochloride (GuHCl) (see 2.1.16) to give a final haematocrit of 4 %. Separate suspensions were 
incubated at 37 ºC for 5, 10, 15, and 20 minutes respectively. Cells were centrifuged at 1800 rpm for 
5 minutes at room temperature and supernatant was removed. The RBC pellet was washed three times 
with PBS (see 2.1.13) then resuspended in P. cynomolgi culture media (see 2.1.2).  
 
2.2.11 P. cynomolgi schizont stage synchronisation using Magnetic Activated Cell Sorting 
(MACS) 
Segmenting P. cynomolgi schizonts (~46 hours) were centrifuged at 1800 rpm for 5 minutes 
at room temperature and supernatant was removed. The RBC pellet was resuspended to ~50 % 
haematocrit using RPMI 1640 with L-glutamine and 25mM HEPES (Cat. No. 22400089, Gibco). The 
MACs column (Cat. No. 130-042901, Miltenyi Biotec) was inserted into the stand. The column was 
wet using RPMI 1640 with L-glutamine and 25mM HEPES (Cat. No. 22400089, Gibco). Once the 
media started to drip through the column the RBC suspension was gently pipetted on top of the 
magnetic beads in the column. RPMI 1640 with L-glutamine and 25mM HEPES (Cat. No. 22400089, 
Gibco) was added as needed until the column dripped clear. The column was topped up with RPMI 
1640 with L-glutamine and 25mM HEPES (Cat. No. 22400089, Gibco) and carefully removed from 
the stand. Using the plunger, the schizonts were removed from the column by forcefully pushing the 
plunger through. Cells were centrifuged at 1800 rpm for 5 minutes at room temperature and 
supernatant was removed.  
 
2.2.12  Schizont concentration using 26.7 % (w/v) Nycodenz 
P. cynomolgi schizonts were centrifuged at 1800 rpm for 5 minutes at room temperature and 
supernatant was removed. The RBC pellet was resuspended to ~50 % haematocrit using RPMI 1640 
with L-glutamine and 25mM HEPES (Cat. No. 22400089, Gibco).  A 55 % Nycodenz/RPMI solution 
(v/v) was prepared from the Nycodenz stock solution (see 2.1.18). Then 8 mL of 55 % Nycodenz was 
added to a 15 mL falcon tube. Holding the falcon tube at an angle, the RBC suspension was very 
slowly pipetted to ‘float’ on top of the 55 % Nycodenz solution taking care not to disturb the layer 
that forms. Cells were centrifuged at 900 g for 12 minutes (acceleration 4, and deceleration 1) at room 
temperature. The interface (consisting of schizonts) is carefully collected and washed three times with 
PBS (see 2.1.13).  
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2.2.13  Transfection of P. cynomolgi parasites  
  P. cynomolgi late stage schizonts (~46 hours) were centrifuged at 1800 rpm for 5 minutes at 
room temperature and supernatant was removed. The infected RBC pellet was resuspended to ~50 
percent haematocrit using RPMI 1640 with L-glutamine and 25mM HEPES (Cat. No. 22400089, 
Gibco). The RBC suspension was ‘floated’ on top of a 55 % Nycodenz solution (see 2.1.18). Cells 
were centrifuged at 900 g for 12 minutes (acceleration 4, and deceleration 1) at room temperature.  
The interface (consisting of schizonts) is carefully collected and washed three times with PBS (see 
2.1.13). The infected RBC pellet was resuspended in 8 mL of compound 2 media (see 2.1.4) and 
incubated at 37 ºC for up to 3 hours or until there is >3 % late segmenting schizonts.  
While culture was being treated with compound 2 media the electroporation mix and recovery media 
were prepared. For transfections with a single plasmid, electroporation mix required 20 µg of plasmid 
DNA per 1.5 mL Eppendorf made up to 100 µL using P3 primary cell solution (Cat. No. V4XP-3024, 
Lonza). For transfections with single stranded oligodeoxynucleotide (ssODN) and plasmid, 
electroporation mix required 15 µg of ssODN and 7 µg of plasmid DNA per 1.5 mL Eppendorf made 
up to 100 µL using P3 primary cell solution.  For recovery media 150 µL of uninfected M. fascicularis 
RBCs were suspended in 500 µL of P. cynomolgi culture media (see 2.1.2) in a 1.5 mL microfuge 
tube and incubated until needed.  
The culture was centrifuged at 1800 rpm for 5 minutes at room temperature and compound 2 media 
was removed. The infected RBC pellet was washed three times with P. cynomolgi culture media (see 
2.1.2). ~5 µL of infected RBCs were gently added to the pre-prepared electroporation mix and 
carefully transferred into the Nucleocuvette TM vessel (Cat. No. V4XP-3024, Lonza). The cells were 
electroporated using the Amaxa 4D Nucleofactor (Cat. No. AAF-1002X, Lonza). The electroporated 
mix was carefully and quickly resuspended into the pre-warmed recovery media.  Cells were 
incubated at 37 ºC on shaker at 600 rpm for 40 minutes then added to 4.5 mL of P. cynomolgi culture 
media (see 2.1.2) in a culture well. Culture wells were moved to chamber, gassed with trimix gas, 
and incubated at 37 ºC.   
Transfection culture media was replaced daily for 48 hours, and then placed on WR99210 drug media 
(see 2.1.5). Cultures were monitored by assessing thin smears (see 2.2.8) and WR99210 drug media 
was replaced daily for 7 days. By day 7 after transfection, parasites were no longer detectable and 
drug pressure was removed, and P. cynomolgi culture media (see 2.1.2) was subsequently replaced 
every 2 days.  Later in the study, it was decided that parasites should remain on WR99210 drug media 
indefinitely. 
 49 
Cultures were then monitored by weekly thick smears (see 2.2.8). Weekly, 50 µL of uninfected M. 
fascicularis RBCs were added to replace old and lysing RBCs.  
 
2.2.14  P. cynomolgi DNA extraction and Sanger sequencing 
 To extract DNA from our P. cynomolgi Berok strain, the QIAGEN DNeasy Blood and Tissue 
kit (Cat. No. 69504, QIAGEN) was used according to the manufacturer’s instructions. PCR was 
performed using the KAPA HiFi HotStart ReadyMixPCR Kit (Cat. No. 07958935001, Roche) to 
amplify P. cynomolgi DNA using 10 µM of primers (Table 2.4) flanking the gene targeted for 
CRISPR manipulation. Sanger sequencing was performed by the Genetic Analysis Services, 
Department of Anatomy, the University of Otago using primers to check for CRISPR mutations 
(Table 2.2). 
Table 2.2: Primers for sequencing CRISPR mutations 






2.3  Plasmodium gene sequence comparison 
2.3.1  Plasmodium strains 
Plasmodium strains used in this study are shown in Table 2.3. 
Table 2.3: Plasmodium strains used in this study for cloning 
Strain Source 
Plasmodium cynomolgi Berok K4A7 (lab 
clone) 
Professor Dennis E. Kyle (University of Georgia). 
Plasmodium cynomolgi Berok (sequence) 
Professor Juan Pablo Bifani (National University 
of Singapore) 
Plasmodium falciparum 3D7 
PlasmoD: a functional genomic database for 
malaria parasites (238). 
Plasmodium vivax Sal-1 
PlasmoD: a functional genomic database for 
malaria parasites (238). 
Plasmodium cynomolgi B strain 
PlasmoD: a functional genomic database for 
malaria parasites (238). 
 
2.3.2 Multiple sequence alignment of the cytb gene   
Table 2.4: P. cynomolgi Berok sequencing primers for the cytb gene 






To extract DNA from our P. cynomolgi Berok lab clone, the QIAGEN DNeasy Blood and Tissue kit 
(Cat. No. 69504, QIAGEN) was used according to the manufacturer’s instructions. PCR was 
performed using the KAPA HiFi HotStart ReadyMixPCR Kit (Cat. No. 07958935001, Roche) to 
amplify P. cynomolgi Berok DNA using 10 µM of Cytb_seq_F_3 and Cytb_seq_R_3 primers (Table 
2.4) flanking the cytb gene. Sanger sequencing was performed by the Genetic Analysis Services, 
Department of Anatomy, the University of Otago using all cytb sequencing primers (Table 2.4). 
The P. cynomolgi Berok genome sequence was gifted to us by Professor Juan Pablo Bifani (National 
University of Singapore). SeqMan Pro (DNASTAR, Lasergene) was used to align the Sanger 
sequencing of cytb from the P. cynomolgi Berok lab clone with the full P. cynomolgi Berok sequence 
to confirm the lab clone was the correct strain.  
P.falciparum 3D7, P. vivax Sal-1, and P. cynomolgi B strain cytb gene nucleotide and protein 
sequences were downloaded from PlasmoD (238). Alignment and pairwise comparison of both 
nucleotide and protein sequences from the four Plasmodium spp. was performed using MegAlign Pro 
(DNASTAR, Lasergene).   
 
2.3.3 Multiple sequence alignment of the CRT gene   
Table 2.5: P. cynomolgi Berok sequencing primers for the crt gene 






To extract DNA from our P. cynomolgi Berok lab clone, the QIAGEN DNeasy Blood and Tissue kit 
(Cat. No. 69504, QIAGEN) was used according to the manufacturer’s instructions. PCR was 
performed using the KAPA HiFi HotStart ReadyMixPCR Kit (Cat. No. 07958935001, Roche) to 
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amplify P. cynomolgi Berok DNA using 10 µM of CRT_seq_F_1 and CRT_seq_R_1 primers (Table 
2.5) flanking the crt gene. Sanger sequencing was performed by the Genetic Analysis Services, 
Department of Anatomy, the University of Otago using all crt sequencing primers (Table 2.5). 
SeqMan Pro 17.2.1 (DNASTAR, Lasergene) was used to align the Sanger sequencing of crt from the 
P. cynomolgi Berok lab clone with the full P. cynomolgi Berok sequence to confirm the clone was 
the correct strain.  
P.falciparum 3D7, P. vivax Sal-1, and P. cynomolgi B strain crt gene nucleotide, messenger 
ribonucleic acid (mRNA), and protein sequences were downloaded from PlasmoD (238). Alignment 
and pairwise comparison of both nucleotide and protein sequences from the four Plasmodium spp. 









2.4  Design of CRISPR plasmid 
2.4.1  Bacterial strains  
Bacterial strains used in this study are shown in Table 2.6 
Table 2.6: Bacterial strains used in this study. 
Strain Source 
TOP10 chemically competent Escherichia coli McLellan Lab (University of Otago) 
DH5α competent E. coli Fineran Lab (University of Otago) 
 
2.4.2  CaCl2 competent TOP10 E. coli  
 A starter culture was made by inoculating 3 mL of LB media (see 2.1.22) with a pipette 
touched to a single colony of TOP10 E. coli and incubated overnight at 37 ºC shaking at 200 rpm. 
200 mL of LB media in a conical flask was inoculated with 2 mL of starter culture and returned to 
the shaking incubator at 37 ºC and 200 rpm until the culture reached an optical density (OD)600 of 
0.35-0.45. The culture was transferred to pre-cooled 50 mL falcon tubes and incubated in an ice water 
bath for 20 minutes. The culture was centrifuged at 2000 g for 10 minutes at 4 ºC, and supernatant 
was removed. The pellet was resuspended in 20 ml of pre-cooled 75 mM CaCl2/10 mM PIPES/15 % 
glycerol and incubated in an ice water bath for 20 minutes. The culture was centrifuged at 2000 g for 
10 minutes at 4 ºC, and supernatant was removed. The pellet was resuspended in 2 ml of pre-cooled 
75 mM CaCl2/10 mM PIPES/15 % glycerol and incubated in an ice water bath for 20 minutes. The 
culture was centrifuged at 2000 g for 10 minutes at 4 ºC, and supernatant was removed. The cell 
suspension was aliquoted into 55 µL volumes in pre-chilled (at -80 ºC) 0.65 µL Eppendorf’s. Tubes 
were transferred directly into a pre-chilled storage box and stored in -80 ºC until use.  
 
2.4.3  Inoue competent DH5 α E. coli  
 DH5α E. coli was freshly streaked from -80 ºC onto a LB agar plate (see 2.1.25) and incubated 
for 12-16 hours at 37 ºC. Single colonies were selected for two 5 mL overnight cultures in LB broth 
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(see 2.1.22) and incubated for 12-16 hours at 37 ºC. Using one of the two overnight cultures; one 1 L 
flask with 200 mL SOC media (see 2.1.24) was inoculated with 0.2 mL of overnight culture, one 1 L 
flask with 200 mL SOC media is inoculated with 0.5 mL of overnight culture, and one 1 L flask with 
200 mL SOC media is inoculated with 2 mL of overnight culture. All three cultures were left to 
incubate overnight at 18 ºC at 180 rpm. The OD600 of all three cultures was measured every 60   
minutes until one of the cultures reached an OD600 of 0.5 (between 0.4 and 0.6 was accepted). The 
culture was transferred to wet ice for 15 minutes (swirled periodically). Cells were transferred to pre-
chilled 50 mL flacon tubes. Cells were centrifuged at 2500 g for 10 minutes at 4 ºC and supernatant 
was discarded. The bacteria in each falcon tube were resuspended gently in 10 mL of ice-cold Inoue 
transformation buffer (see 2.2.33). Cells were transferred to a single falcon tube and topped up to 50 
mL with ice-cold Inoue transformation buffer. Cells were centrifuged at 2500 g for 5 minutes at 4 ºC, 
and supernatant was discarded. On ice, bacteria were resuspended gently in 20 mL of ice-cold Inoue 
transformation buffer. Drop-by-drop, 1.5 mL of DMSO was added while swirling. Cells were left on 
ice for 10 minutes. The cell suspension was aliquoted into 55 µL and 110 µL volumes in pre-chilled 
(at -80 ºC) 0.65 µL Eppendorf’s. Cells were left to sit in a dry ice/ethanol bath until they freeze. Tubes 
were transferred directly into a pre-chilled storage box and stored in -80 ºC until use.  
 
2.4.4  Electro-competent DH5 α E. coli  
 DH5α E. coli was freshly streaked from -80 ºC onto a LB agar plate (see 2.1.25) and 
incubated for 12-16 hours at 37 ºC. A single colony was selected and used to inoculate 5 mL of LB 
media (see 2.1.23) and incubated overnight at 37 ºC shaking at 200 rpm. A 200 mL volume of LB 
media was inoculated with 1 mL of the overnight culture and incubated at 37 ºC. Growth was 
monitored by until OD600 reaches 0.35-0.4. The culture was aliquoted into 4 pre-chilled 50 mL 
falcon tubes and cooled on ice for 10 minutes. The culture was then centrifuged at 4000 rpm for 20 
minutes at 4 ºC, and supernatant was discarded. The pellet was resuspended in 5 mL of ice-cold 
sterile MilliQ. The re-suspended cells were unified into 2 falcon tubes and sterile MilliQ was added 
up to 50 mL. The culture was centrifuged at 4000 rpm for 10 minutes at 4 ºC, and supernatant was 
discarded. The pellet was again resuspended in 5 mL of ice-cold sterile MilliQ, and sterile MilliQ 
was added up to 50 mL. The culture was centrifuged at 4000 rpm for 10 minutes at 4 ºC, and 
supernatant was discarded. The pellet was re-suspended in 5 mL of pre-chilled 10 % glycerol and 
the suspended cells were unified into 1 falcon tube and pre-chilled 10 % glycerol was added to 50 
mL. The culture was centrifuged at 4000 rpm for 10 minutes at 4 ºC, and supernatant was discarded. 
The pellet was resuspended in 1 mL of pre-chilled 10 % glycerol.  As an optional step, 70 µL of 
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cells were put into a microcuvette and used to test for arching. If arching occurred, then cells were 
washed once more with pre-chilled 10 % glycerol. The cells were aliquoted in 75 µL volumes into 
pre-chilled (at -80 ºC) 0.65 mL Eppendorfs, and shock frozen in liquid nitrogen before being moved 
to the -80 ºC freezer for storage until use.  
 
2.4.5 Plasmids 
Plasmids used in the design and construction of CRISPR plasmids are shown in Table 2.7 
Table 2.7: Plasmids used in this study 
Plasmid Features 
pGEM-T-Easy (Cat. No. A362A, Promega) Linearized cloning vector 
pGEM_K12 From Kurt Ward (University of 
Otago, PhD student) 
pGEM-T-Easy plasmid with K12 gene 
donor template insert 
pGEM 
A derivative of pGEM_K12 plasmid, with 
K12 gene removed 
pGEM_Cytb 
pGEM plasmid with cytb gene donor 
template insert 
pDC2_vCAM_Cas9_U6_hDHFR Cas9 plasmid 
Cytb_pDC2_vCAM_Cas9_U6_hDHFR_gRNA2 
Cas9 plasmid with specific gRNA 2 for 
cytb 
Cytb_pDC2_vCAM_Cas9_U6_hDHFR_gRNA4 
Cas9 plasmid with specific gRNA 4 for 
cytb 
pGEM_cytb_BSM2 
pGEM_cytb plasmid with BSMs for 
gRNA 2 
pGEM_cytb_Y268S_BSM2 
pGEM_cytb_BSM2 plasmid with Y268S 
mutation 
pGEM_cytb_BSM4 








Cas9 plasmid with specific gRNA 4, and 
BSM for gRNA 4 
pDC2_vCAM_Cas9_U6_hDHFR_gRNA4_Cytb_
Y268S_BSM4 
Cas9 plasmid with specific gRNA 4, 
Y268S mutation, and BSM4 for gRNA 4 
CRT_pDC2_vCAM_Cas9_U6_hDHFR_gRNA1 Cas9 plasmid with specific gRNA 1 for crt 
CRT_pDC2_vCAM_Cas9_U6_hDHFR_gRNA2 Cas9 plasmid with specific gRNA 2 for crt 
 
2.4.6 Single stranded Oligodexoynucleotides 
Single stranded oligodeoxynucleotide (ssODN) used in this study are shown in Table 2.8. 
These were purchased from IDT (Integrated DNA Technologies).  The full ssODN sequence is 
located in Appendix 2 and Appendix 3. 
Table 2.8: ssODNs used in this study. 
ssODNs Features 
CRT_K76T_BSM1 
Crt gene open reading frame 2 containing K76T 
mutation and gRNA1 binding site mutations 
(BSMs) 
CRT_K76T_BSM2 
Crt gene open reading frame 2 containing K76T 
mutation and gRNA2 BSMs 
 
2.4.7 Guide RNA selection and design 
 The protospacer adjacent motif (PAM) sites were identified in the P. cynomolgi cytb and crt 
gene by our collaborators Vipin Narang (Singapore Immunology Network, Singapore) and Pablo 
Bafani (National University of Singapore, Singapore). 
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The PAM sites targeted by the gRNAs in Table 2.9 were selected based on their efficacy, distance 
from the mutation site, and uniqueness. The gRNAs oligos were designed with bbsI overhangs (Table 
2.10) for insertion into the pDC2_vCam_Cas9_U6_hDHFR plasmid according to the methods laid 
out by Marcus Lee (239).  
Table 2.9: Guide RNA (gRNA) primer sequences and efficacies. PAM sites are coloured green. 
gRNA name gRNA sequence (plus PAM) gRNA efficacy 
Cytb_Guide 2 CAATTCAAATTGTTCCTGAATGG 0.05 
Cytb_Guide 4 TTCTATGCTTTATTATGGATTGG 0.15 
CRT_Guide 1 TATTCATAACACATACACACAGG 0.37 
CRT_Guide 2 AAGAGGACTCTGAAGAAAATGGG 0.32 
 
Table 2.10: gRNA oligonucleotides (oligo) sequences. BbsI overhangs in red. 











2.4.8 Repair template primers  
 Binding site mutations (BSMs) were designed to disrupt the PAM site (Table 2.11).  If silent 
mutations could not be designed for the PAM site, then 2-4 silent mutations are introduced elsewhere 
in target sequence to make it non-complementary to the gRNA.   
Table 2.11: Gene mutation sequences. Mutations lowercase and bolded. PAM sites coloured green. 
Mutation 
name 
Original sequence Mutation sequence 
Cytb_Y268S TTACCATTTTATGCAATGTTAA TTACCATTTTcTGCAATGTTAA 
Cytb_BSM2 CAATTCAAATTGTTCCTGAATGG CAATTCAgATaGTaCCcGAATGG 
Cytb_BSM4 TTCTATGCTTTATTATGGATTGG TTCTAcGCaTTgTTgTGGATTGG 
CRT_K76T GTGTTATGAATAAAATTTTAGCA GTGTTATGAATAcAATTTTAGCA 
CRT_BSM1 TATTCATAACACATACACACAGG TATTCATAACACATACACACAGa 
CRT_BSM2 AAGAGGACTCTGAAGAAAATGGG AAGAGGACTCTcAAaAAgATGGG 
To amplify the P. cynomolgi genes, donor template (annotated as DNR) primers were designed with 
SfoI and AatII restriction site tags respectively (Table 2.12).  In the case of crt, these were later 
changed to both have SfoI restriction site tags (Table 2.12).  
Primers to introduce BSMs and drug resistance by site directed mutagenesis (SDM) were designed 
for both cytb and crt using SeqBuilder Pro (DNASTAR, Lasergene) (Table 2.12).  
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Table 2.12: Primer sequences and annealing temperatures for sequencing, donor template 
amplification and site directed mutagenesis. Restriction site tags for SfoI (red) and AatII (purple) are 
coloured. 
Primer name Primer sequence 
Annealing 
temperature 
M13R CAGGAAACAGCTATGAC N/A 
M13F GTAAAACGACGGCCAGT N/A 
Temp1 CCCTGGCGTTACCCAACTTAATCG N/A 
Cytb_seq_F_1 CGTATTCCTGATTATCCAGACGC N/A 
Cytb_seq_R_1 AGCTGAACCAAAATGGCTGC N/A 
Cytb_seq_M_1 TTTGGTTATGTGGAGGATATACAGT N/A 
Cytb_seq_M_2 TGGTTATGTGGAGGATATACAGTAAGT N/A 
CytB_F_dnr_1 TTTGGCGCCTGAGTTATTGGGGTGCAACTGT 
























CRT_seq_M_1 CACTGGTGATGGTGTCCCAA N/A 
CRT_seq_M_2 AGCGCAATTCGAGGGTGTTA N/A 






CRT_R _dnr_2 TTTCCGCGGTAAAGCGAAGCGGTCACCTT 
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2.5  Production of cytb Cas9 plasmids for transfection 
 
Figure 2.2: Methods Figure for the production of pDC2_vCam_Cas9_U6_hDHFR. The cytb gene DNA 
extracted from P. cynomolgi or ordered cytb geneblock was ligated into pGEM or pGEM-T-Easy plasmids. 
Red crosses indicate failed techniques for cloning. Site directed mutagenesis (SDM) was performed to 
introduce the desired mutation (Y268S) and binding site mutations (BSMs) into the donor template. Mutated 
donor template and guide RNAs (gRNAs) were ligated into pDC2_vCam_Cas9_U6_hDHFR plasmid. 
Human DHFR (hDHFR) is the drug resistance cassette. Asterix (*) represents Y268S and BSMs. 
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2.5.1 Restriction digest of pDC2_vCam_Cas9_U6_hDHFR plasmid 
The pDC2_vCam_Cas9_U6_hDHFR plasmid is a variant of Marcus Lee’s 2969 plasmid, and 
cloning was initially carried out as per his instructions (239). The pDC2_vCam_Cas9_U6_hDHFR 
plasmid was digested using 7.5 units of the restriction enzyme BbsI (Cat. No. R0539L, NEB) for 3 
hours at 37 ºC, then dephosphorylated using 1 unit of Calf-intestinal phosphatase (CIP) (Cat. No. 
M0290, NEB) for a further 30 minutes at 37 ºC.   
 
2.5.2 PCR clean-up of pDC2_vCam_Cas9_U6_hDHFR plasmid 
To remove restriction enzymes and buffers, a PCR clean-up was performed using the Monarch 
PCR & DNA Clean-up Kit (Cat. No. T1030, Monarch). In brief, for a plasmid >2 kb a 2:1 ratio of 
binding buffer:sample was used to dilute sample. Diluted sample was loaded into a spin column and 
centrifuged at 13, 000 rpm for 1 minute at room temperature, and the supernatant was discarded.  The 
sample was washed twice by adding 200 µL of DNA wash buffer to the spin column and centrifuging 
at 13, 000 rpm for 1 minute at room temperature, and discarding the supernatant. The spin column 
was transferred to a clean 1.5 mL Eppendorf, and 10 µL of MilliQ water was added to the centre of 
the matrix and incubated at room temperature for 1 minute. The sample was centrifuged at 13, 000 
rpm for 1 minute at room temperature to elute DNA. The digested plasmid concentration was 
measured using the ThermoScientificTM NanodropTM Spectrophotometer (Cat. No. 13400518, Fisher 
scientific). 
 
2.5.3 Annealing cytb gRNAs  
The cytb gRNAs oligos (Table 2.10) were annealed using the T4 Polynucleotide kinase (Cat. 
No. M0201S, NEB), according to Marcus Lees instructions (239).  In brief, gRNA pairs were annealed 
using T4 polynucleotide kinase (Cat. No. M0201S, NEB). The ligation mix was incubated at 37 ºC 





2.5.4 Sticky end ligation of annealed cytb gRNAs with BbsI digested 
pDC2_vCam_Cas9_U6_hDHFR plasmid 
The annealed oligos were ligated at 16 ºC overnight into pDC2_vCam_Cas9_U6_hDHFR 
plasmid using T4 DNA ligase (Cat. No. M0202L, NEB) according to manufacturer’s instructions.   
 
2.5.5 Transformation of cytb_pDC2_vCam_Cas9_U6_hDHFR_gRNAs into TOP10 E. coli 
The cytb_pDC2_vCam_Cas9_U6_hDHFR_gRNA2 and cytb_-
pDC2_vCam_Cas9_U6_hDHFR_gRNA4 plasmids were individually transformed into TOP10 E. 
coli using a heat shock protocol. Ice thawed TOP10 E. coli was transferred into a pre-cooled 1.5 mL 
Eppendorf and mixed gently with 1 pg-100 ng of plasmid DNA, then incubated on ice for 30 minutes. 
The cells were heat shocked at 42 ºC for 40 seconds then placed back on ice for 2 minutes. 300 µL 
of room temperature LB broth (see 2.1.22) was added to the bacteria and incubated for 1 hour at 250 
rpm and 37 ºC. 300 µL of sample was plated onto room temperature LB-agar plates with ampicillin 
(see 2.1.26) then incubated overnight at 37 ºC.   
 
2.5.6 Miniprep of cytb_pDC2_vCam_Cas9_U6_hDHFR_gRNA plasmids 
Using the Monarch Plasmid Miniprep Kit (Cat. No. T1010L, Monarch), the plasmid DNA 
was extracted and purified from E. coli according to the manufacturer’s instructions. In brief, 5 mL 
of LB broth with ampicillin (see 2.1.23) was inoculated with a single colony picked from 
transformation plates and grown overnight at 37 ºC shaking at 200 rpm. 1.5 mL of bacterial culture 
was centrifuged at 13, 000 rpm for 1 minute at room temperature and supernatant was discarded. The 
bacterial pellet was thoroughly resuspended in 200 µL of pink resuspension buffer. 200 µL of blue 
lysis buffer was added to suspension for 1 minute at room temperature. 400 µL of yellow 
neutralisation buffer was added and mixed gently by inversion for 1 minute (or until colour was 
uniformly yellow and precipitate formed) and incubated for 2 minutes.  The suspension was 
centrifuged at 16, 000 rpm for 5 minutes at room temperature. The supernatant was loaded into spin 
column and centrifuged at 13, 000 rpm for 1 minute at room temperature and supernatant was 
discarded. 200 µL of Plasmid wash buffer 1 was added and spin column was centrifuged at 13, 000 
rpm for 1 minute at room temperature and supernatant was discarded. 400 µL of Plasmid wash buffer 
2 was added and spin column was centrifuged at 13, 000 rpm for 1 minute at room temperature and 
 64 
supernatant was discarded. The spin column was transferred to a clean 1.5 mL Eppendorf and 50 µL 
of MilliQ water was added to the centre of the matrix and incubated at room temperature for 1 minute. 
The spin column was centrifuged at 13, 000 rpm for 1 minute at room temperature to elute DNA. The 
plasmid concentration was measured using the ThermoScientificTM NanodropTM Spectrophotometer 
(Cat. No. 13400518, Fisher scientific). 
 
2.5.7 Sanger sequencing to check gRNA insertion into pDC2_vCam_Cas9_U6_hDHFR 
plasmid 
Sanger sequencing was performed by the Genetic Analysis Services, Department of Anatomy, the 
University of Otago using the M13R primer (Table 2.12) to confirm gRNA insertion into the Cas9 
plasmid. 
 
2.5.8 Maxiprep of complete Cas9_gRNA plasmids 
 The confirmed pDC2_vCam_Cas9_U6_hDHFR_gRNA plasmids were maxiprepped using 
the Macherey-Nagel Plasmid DNA purification kit NucleoBond Xtra Maxi Plus (Cat. No. 740416.50, 
Macherey-Nagel). In brief, a starter culture was produced by inoculating 5 mL of LB broth with 
ampicillin (see 2.1.23) with 1 mL of the miniprep overnight culture and grown overnight at 37 ºC 
shaking at 200 rpm. 600 mL of LB broth with ampicillin (see 2.1.23) was inoculated with 1 mL of 
stater culture and grown at 37 ºC shaking at 200 rpm for 12-16 hours. Bacteria were centrifuged at 6, 
000 g for 10 minutes at 4 ºC and supernatant was discarded. Bacteria was resuspended in 24 mL of 
Resuspension buffer. 24 mL of lysis buffer was added to suspension for 5 minutes. 24 mL of 
Neutralisation buffer was added to the suspension and inverted until blue colour has completely 
disappeared. The suspension was centrifuged at 6, 000 g for 10 minutes at 4 ºC and supernatant was 
added to the pre-equilibrated NucleoBond Xtra column filter. Once all the supernatant had passed 
through the filter, 15 mL of Equilibration buffer was added for the first wash. The filter was removed, 
and 25 mL of Wash buffer was added to the NucleoBond Xtra column for the second wash. A 50 mL 
falcon was placed under the column and 15 mL of Elution buffer was added to elute DNA. 10.5 mL 
of room temperature isopropanol was added, vortexed well, then left to sit for 2 minutes. The 
suspension was loaded into the supplied 30 mL syringe attached to the NuceloBond Finaliser and 
slowly plunged through the finaliser. The flow through was discarded. 4 ml of 70 % ethanol was 
loaded into the same syringe and slowly plunged through the filter. The flow through was discarded. 
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To dry the finaliser air was forcefully plunged through the filter as many times as necessary until 
there was no more ethanol exiting the filter (~6 times). The finaliser was attached to the supplied 1 
mL syringe and 1 mL of MilliQ water was slowly plunged through to elute plasmid DNA into a clean 
1.5 mL Eppendorf. The eluted DNA was reloaded into the 1 mL syringe and slowly plunged through 
the filter once more. Air was plunged through the finaliser to elute as much eluate as possible. The 
plasmid concentration was measured using the ThermoScientificTM NanodropTM Spectrophotometer 
(Cat. No. 13400518, Fisher scientific). 
 
2.5.9 PCR amplification of cytb donor template 
 Previously extracted (see 2.2.14) P. cynomolgi Berok DNA was amplified using the KAPA 
HiFi HotStart ReadyMixPCR Kit (Cat. No. 07958935001, Roche) according to the manufacturer’s 
instructions. In brief, for a 25 µL PCR, 25 ng of P. cynomolgi Berok DNA was mixed gently with the 
2X KAPA HiFi HotStart ReadyMix and 10 µM of the cytb donor template primers CytB_F_dnr_1 
and CytB_R_dnr_1 (Table 2.12). The PCR reaction was run through the kit specified thermocycler 
protocol. PCR products were run on a 1 % agarose gel (see 2.1.30) at 120 V for 1 hour.  
 
2.5.10 PCR amplification of cytb donor template geneblock 
 A gene block (Appendix 1) was purchased from IDT (Integrated DNA Technologies) and 
PCR amplified to add restriction tags SfoI and AatII. Amplification was performed using the KAPA 
HiFi HotStart ReadyMixPCR Kit (Cat. No. 07958935001, Roche) according to the manufacturer’s 
instructions. In brief, for a 25 µL PCR, 25 ng of cytb gene block was mixed gently with the 2X KAPA 
HiFi HotStart ReadyMix and 10 µM of the cytb donor template primers CytB_F_dnr_1 and 
CytB_R_dnr_1 (Table 2.12). The PCR reaction was run through the kit specified thermocycler 
protocol. PCR products were run on a 1 % agarose gel (see 2.1.30) at 120 V for 1 hour.  
 
2.5.11 Gel extraction of PCR products 
Products run on 1 % agarose gel had their appropriate bands extracted using the Monarch Gel 
Extraction kit (Cat. No. T1020L, Monarch) according to manufacturer’s instructions. In brief, specific 
DNA fragments were excised from the agarose gel and transferred to a clean 1.5 mL Eppendorf and 
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weighed. The gel dissolving buffer was added to be 4 times the volume of the gel slice. The sample 
was incubated at ~50 ºC until the gel slice was completely dissolved. The sample was loaded into a 
spin column and centrifuged at 13, 000 rpm for 1 minute at room temperature, and supernatant was 
discarded. The sample was washed twice by adding 200 µL of DNA wash Buffer to the spin column 
and centrifuging at 13, 000 rpm for 1 minute at room temperature, and supernatant was discarded. 
The spin column was transferred to a clean 1.5 mL Eppendorf, and 10 µL of MilliQ water was added 
to the centre of the matrix and incubated at room temperature for 1 minute. The sample was 
centrifuged at 13, 000 rpm for 1 minute at room temperature to elute DNA. The digested plasmid 
concentration was measured using the ThermoScientificTM NanodropTM Spectrophotometer (Cat. No. 
13400518, Fisher scientific). 
 
2.5.12 TA cloning (blunt end ligation) of cytb donor templates with pGEM-T-easy vector 
 The pGEM-T-easy vector (Cat. No. A362A, Promega) was used as an intermediate vector. It 
is a linerised vector with a single 3’-terminal thymidine at both ends and an ampicillin selection 
marker.  A-tailing of the cytb donor template was performed using AmpliTaq Gold DNA polymerase 
(Cat. No. 4311806, Applied Biosystems), incubated at 70 ºC for 30 minutes.  
A-tailed cytb donor templates were ligated overnight with the pGEM-T-easy vector using T4 DNA 
ligase (Cat. No. M0202L, NEB) according to manufacturer’s instructions. 
 
2.5.13 Transformation of pGEM_cytb into TOP10 E. coli 
 The pGEM_cytb plasmid was transformed into TOP10 E. coli using a heat shock protocol as 
previously described in 2.5.5 and plated onto Luria-Bertani (LB) agar plates with X-gal, IPTG, and 
ampicillin (see 2.1.27).  
 
2.5.14 Restriction digest of cytb donor templates and pGEM vector 
 The pGEM_K12 plasmid (previously made by Kurt Ward, Otago University, PhD student) 
and cytb donor templates were digested using 7.5 units of the restriction enzymes SfoI (Cat. No. 
R0606L, NEB) and AatII (Cat. No. R0117L, NEB) for 3 hours at 37 ºC. The digested pGEM plasmid 
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was dephosphorylated using 1 unit of CIP (Cat. No. M0290, NEB) for a further 30 minutes at 37 ºC.  
The digested products were run on a 1 % agarose gel (see 2.1.30) at 120 V for 1 hour, and gel extracted 
as described in 2.5.10. 
 
2.5.15 Sticky end ligation of cytb donor templates with pGEM 
 The digested cytb donor templates and pGEM plasmid were ligated using T4 DNA ligase 
(Cat. No. M0202L, NEB) according to manufacturer’s instructions (as described in 2.5.4).  
 
2.5.16 Transformation of pGEM_cytb into TOP10 E. coli 
 The pGEM_cytb plasmid was transformed into TOP10 E. coli using a heat shock protocol as 
described in 2.5.5.  
 
2.5.17 Miniprep of pGEM_cytb 
 4-6 colonies were selected from transformation plates and incubated in 5 mL of LB broth with 
ampicillin (see 2.1.23) overnight shaking at 200 rpm at 37 ºC.  
Using the Monarch Plasmid Miniprep Kit (Cat. No. T1010L, Monarch), plasmids were purified 
according to the manufacturer’s instructions (as previously described in 2.5.6). The plasmid 
concentration was measured using the ThermoScientificTM NanodropTM Spectrophotometer (Cat. No. 
13400518, Fisher scientific). 
  
2.5.18 Restriction digest to confirm ligation of cytb donor templates with pGEM 
 Extracted pGEM_cytb plasmids were digested using 7.5 units of the restriction enzymes SfoI 
(Cat. No. R0606L, NEB) and AatII (Cat. No. R0117L, NEB) for 1 hour at 37 ºC. The digested 
products were run on a 1 % agarose gel (see 2.1.30) at 120 volts (V) for 1 hour.  
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2.5.19 Sanger sequencing to check cytb donor template insertion into pGEM 
 If 1.5kb (cytb donor template insert) and 3kb (pGEM vector) bands were present in the 
restriction digest products once run on a gel (see 2.5.17), the pGEM_cytb plasmids were sequenced 
by the Genetic Analysis Services, Department of Anatomy, The University of Otago using the M13R, 
Temp1, and p283 primers and cytb sequencing primers (Table 2.12).   
 
2.5.20 Site directed mutagenesis (SDM) of pGEM_cytb 
 Site directed mutagenesis (SDM) was performed to introduce first the Y268S drug resistance 
mutation, then subsequently the binding site mutations (BSMs) for gRNA 4 were also introduced into 
the same donor template. For gRNA 2, because the primers designed for the BSMs overlap the Y268S 
mutation, the BSM needed to be introduced first, followed by the Y268S mutation. 
For the Y268S mutation, the primers Cytb_Y268S_ F and Cytb_Y268S_ R (Table 2.12) were used. 
For introducing the BSMs for gRNA 2, the primers Cytb_BSM2_F and Cytb_BSM2_R (Table 2.12) 
were used. For introducing the BSMs for gRNA 4, the primers Cytb_BSM4_F and Cytb_BSM4_R 
(Table 2.12) were used.   
SDM was performed using the KAPA HiFi HotStart ReadyMixPCR Kit (Cat. No. 07958935001, 
Roche) according to the manufacturer’s instructions. In brief, for a 40 µL reaction, 50 ng of 
pGEM_cytb was mixed gently with the 2X KAPA HiFi HotStart ReadyMix and 10 µM of forward 
and reverse primers. The reaction was run through the kit specified SDM thermocycler protocol.  10 
units of DpnI (Cat. No. R0176S, NEB) was added and incubated for a further 30 minutes at 37 ºC to 
remove all methylated plasmids.  
 
2.5.21 Transformation of SDM plasmids into TOP10 E. coli 
 The pGEM_cytb_Y268S_BSM2, pGEM_cytb_Y268S_BSM4, pGEM_cytb_BSM2, and 
pGEM_cytb_BSM4 plasmids were individually transformed into TOP10 E. coli using a heat shock 




2.5.22 Miniprep of SDM plasmids 
 4-6 colonies were selected from transformation plates and incubated in 5 mL of LB broth with 
ampicillin (see 2.1.23) overnight shaking at 200 rpm at 37 ºC.  
Using the Monarch Plasmid Miniprep Kit (Cat. No. T1010L, Monarch), plasmids were purified 
according to the manufacturer’s instructions (as previously described in 2.5.6). The plasmid 
concentration was measured using the ThermoScientificTM NanodropTM Spectrophotometer (Cat. No. 
13400518, Fisher scientific). 
 
2.5.23 Sanger sequencing to confirm introduction of mutations 
Sanger sequencing was performed by the Genetic Analysis Services, Department of Anatomy, 
the University of Otago using the M13R, M13F, and M1 primer (Table 2.12) to confirm BSM and 
Y268S mutations into the cytb donor template plasmid. 
 
2.5.24 Restriction digest of pGEM_cytb (with mutations) and 
pDC2_vCam_Cas9_U6_hDHFR_gRNA plasmids 
 The pGEM_cytb_Y268S_BSM2, pGEM_cytb_Y268S_BSM4, pGEM_cytb_BSM2, 
pGEM_cytb_BSM4, pDC2_vCam_Cas9_U6_hDHFR_gRNA2, and 
pDC2_vCam_Cas9_U6_hDHFR_gRNA4 plasmids were digested using 7.5 units of the restriction 
enzymes SfoI (Cat. No. R0606L, NEB) and AatII (Cat. No. R0117L, NEB) for 3 hours at 37 ºC. The 
digested products were run on a 1 % agarose gel (see 2.1.30) at 120 V for 1 hour, and gel extracted 
as described in 2.5.10. 
 
2.5.25 Sticky end ligation of cytb donor templates (with mutations) with 
pDC2_vCam_Cas9_U6_hDHFR_gRNA plasmids 
 Digested Cytb_Y268S_BSM2, and Cytb_BSM2, were individually ligated with 
pDC2_vCam_Cas9_U6_hDHFR_gRNA2 using T4 DNA ligase (Cat. No. M0202L, NEB) as 
described in 2.5.4.  
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Digested Cytb_Y268S_BSM4, and Cytb_BSM4, were individually ligated with 
pDC2_vCam_Cas9_U6_hDHFR_gRNA4 using T4 DNA ligase (Cat. No. M0202L, NEB) as 
described in 2.5.4. 
 
2.5.26 Transformation of complete Cas9 plasmids into TOP10 E. coli 
 The pDC2_vCam_Cas9_U6_hDHFR_gRNA4_cytb_Y268S_BSM4, 
pDC2_vCam_Cas9_U6_hDHFR_gRNA4_cytb_Y268S, 
pDC2_vCam_Cas9_U6_hDHFR_gRNA2_cytb_Y268S_BSM2, and 
pDC2_vCam_Cas9_U6_hDHFR_gRNA2_cytb_Y268S plasmids were individually transformed into 
TOP10 E. coli using a heat shock protocol as described in 2.5.5.  
 
2.5.27 Miniprep of complete Cas9 plasmids 
 4-6 colonies were selected from transformation plates and incubated in 5 mL of LB broth with 
ampicillin (2.1.23) overnight shaking at 200 rpm at 37 ºC.  
Using the Monarch Plasmid Miniprep Kit (Cat. No. T1010L, Monarch), plasmids were purified 
according to the manufacturer’s instructions (same as previously described in 2.5.6). The plasmid 
concentration was measured using the ThermoScientificTM NanodropTM Spectrophotometer (Cat. No. 
13400518, Fisher scientific). 
 
2.5.28 Restriction digest to confirm ligation of cytb donor templates with 
pDC2_vCam_Cas9_U6_hDHFR_gRNA4 
 Miniprepped complete Cas9 plasmids were digested using 7.5 units of the restriction enzymes 
SfoI (Cat. No. R0606L, NEB) and AatII (Cat. No. R0117L, NEB) for 1 hour at 37 ºC. The digested 




2.5.29 Sanger sequencing to confirm introduction of ligation 
If 1.5kb (cytb donor template) and 12kb (Cas9 plasmid) bands were present in the restriction 
digest products once run on a gel (see 2.5.27), Sanger sequencing was performed by the Genetic 
Analysis Services, Department of Anatomy, the University of Otago using the temp1, M13R, and 
M13F primers (Table 2.12) to confirm successful ligation. 
  
2.5.30 Maxiprep of complete Cas9 plasmids 
 The confirmed pDC2_vCAM_Cas9_U6_hDHFR_gRNA4_Cytb_BSM4 and 
pDC2_vCAM_Cas9_U6_hDHFR_gRNA4_Cytb_Y268S_BSM4 plasmids were maxiprepped using 
the Macherey-Nagel Plasmid DNA purification kit NucleoBond Xtra Maxi Plus (Cat. No. 740416.50, 















2.6 Production of crt Cas9 plasmids for transfection 
2.6.1 Restriction digest of pDC2_vCam_Cas9_U6_hDHFR plasmid 
The pDC2_vCam_Cas9_U6_hDHFR plasmid was digested using 6.5 units of the restriction 
enzyme BbsI (Cat. No. R0539L, NEB) for 3 hours at 37 ºC, then dephosphorylated using 1 unit of 
CIP (Cat. No. M0290, NEB) for a further 30 minutes at 37 ºC.   
 
2.6.2 PCR cleanup of pDC2_vCam_Cas9_U6_hDHFR plasmid 
To remove restriction enzymes and buffers, a PCR cleanup was performed using the Monarch 
PCR & DNA Cleanup Kit (Cat. No. T1030, Monarch) as previously described in 2.5.2. The digested 
plasmid concentration was measured using the ThermoScientificTM NanodropTM Spectrophotometer 
(Cat. No. 13400518, Fisher scientific). 
 
2.6.3 Annealing crt gRNAs  
The crt gRNAs oligonucleotides (oligos) (Table 2.10) were annealed using T4 Polynucleotide 
kinase (Cat. No. M0201S, NEB), according to Marcus Lees instructions (239) (as described in 2.5.3).  
 
2.6.4 Sticky end ligation of annealed crt gRNAs with BbsI digested 
pDC2_vCam_Cas9_U6_hDHFR plasmid 
The annealed crt oligos were ligated at 16 ºC overnight into pDC2_vCam_Cas9_U6_hDHFR 
plasmid using T4 DNA ligase (Cat. No. M0202L, NEB) according to manufacturer’s instructions (as 
described in 2.5.4.   
 
2.6.5 Transformation of cytb_pDC2_vCam_Cas9_U6_hDHFR_gRNAs into DH5α E. coli 
The crt_pDC2_vCam_Cas9_U6_hDHFR_gRNA1 and crt_-
pDC2_vCam_Cas9_U6_hDHFR_gRNA2 plasmids were individually transformed into DH5α E. coli 
using a heat shock protocol. Ice thawed DH5α E. coli was transferred into a pre-cooled 1.5 mL 
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Eppendorf and mixed gently with 1 pg-100 ng of plasmid DNA, and incubated on ice for 30 minutes. 
Cells were heat shocked at 42 ºC for 40 seconds then placed back on ice for 2 minutes. 300 µL of 
room temperature LB broth (see 2.1.22) was added and sample was incubated for 1 hour at 250 rpm 
and 37 ºC. 300 µL of sample was plated onto room temperature LB-agar plates with ampicillin (see 
2.1.26) then incubated overnight at 37 ºC.   
 
2.6.6 Miniprep of crt_pDC2_vCam_Cas9_U6_hDHFR_gRNA plasmids 
Using the Monarch Plasmid Miniprep Kit (Cat. No. T1010L, Monarch), the plasmid DNA 
was extracted and purified from the E. coli as previously described in 2.5.6.  The plasmid 
concentration was measured using the ThermoScientificTM NanodropTM Spectrophotometer (Cat. No. 
13400518, Fisher scientific). 
 
2.6.7 Sanger sequencing to check gRNA insertion into pDC2_vCam_Cas9_U6_hDHFR 
plasmid 
Sanger sequencing was performed by the Genetic Analysis Services, Department of Anatomy, 
the University of Otago using the M13R primer (Table 2.12) to confirm gRNA insertion into the Cas9 
plasmid. 
 
2.6.8 Maxiprep of complete Cas9_gRNA2 plasmid 
The confirmed pDC2_vCAM_Cas9_U6_hDHFR_gRNA2 plasmid was maxiprepped using 
the Macherey-Nagel Plasmid DNA purification kit NucleoBond Xtra Maxi Plus (Cat. No. 740416.50, 
Macherey-Nagel) as described in 2.5.7. 
 
2.6.9 Approaches to PCR amplification of crt donor template  
 Previously extracted (see 2.2.14) P. cynomolgi Berok DNA was amplified using the KAPA 
HiFi HotStart ReadyMixPCR Kit (Cat. No. 07958935001, Roche) according to the manufacturer’s 
instructions. Variations of this protocol were performed and are shown in Table 2.13. Changes were 
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made to DNA mass, the primers used, primer concentration, annealing temperatures, extension time, 




Table 2.13: Approaches to PCR amplification of the crt gene. 





Extension time Gel electrophoresis 
1 25 ng 
CRT_F_dnr_1 
CRT_R_dnr_1 
10 µM 59.1 ºC 1 min/kb 
1 hour 
120 volts 









3 25 ng 
CRT_F_dnr_2 
CRT_R_dnr_2 
10 µM 58.6 ºC 1 min/kb 
1 hour 
120 volts 
4 25 ng 
CRT_F_dnr_2 
CRT_R_dnr_2 
10 µM 58.6 ºC 30 sec/kb 
1 hour 
120 volts 
5 12.5 ng 
CRT_F_dnr_2 
CRT_R_dnr_2 






6 50 ng 
CRT_F_dnr_2 
CRT_R_dnr_2 
10 µM 58.6 ºC 1 min/kb 
1 hour 
120 volts 
7 25 ng 
CRT_F_dnr_2 
CRT_R_dnr_2 
20 µM 58.6 ºC 1 min/kb 
90 mins 
100 volts 
8 25 ng 
CRT_F_dnr_2 
CRT_R_dnr_2 
10 µM 58.6 ºC 1 min/kb 
3 hours 
80 volts 
9 25 ng 
CRT_F_seq_1 
CRT_R_seq_1 
10 µM 59.1 ºC 1 min/kb 
3 hours 
80 volts 












2.6.10 Gel extraction of PCR products 
Products run on 1 % agarose gel had their appropriate bands extracted using the Monarch Gel 
Extraction kit (Cat. No. T1020L, Monarch) as previously described in 2.5.10. The digested plasmid 
concentration was measured using the ThermoScientificTM NanodropTM Spectrophotometer (Cat. No. 
13400518, Fisher scientific). 
 
2.6.11 Design of single stranded Oligodeoxynucleotide (ssODN)  
 Difficulties to isolate the crt gene from extracted P. cynomolgi Berok DNA lead to the 
purchase of ssODNs from IDT (see 2.4.6). Two ssODNs were purchased, both containing the 





2.7  Production of protein localisation GFP plasmid 
2.7.1 Plasmids 
Plasmids used in this protein localisation study are shown in Table 2.14. 
Table 2.14: Plasmids used in this study. 
Plasmid Features 
pDC2_vCAM_GFP_U6_hDHFR GFP plasmid  
pDC2_vCAM_GFP_U6_hDHFR_DBP2 GFP plasmid with dbp2 gene donor template 
 
2.7.2 Primers 
Primers used in this study are shown in Table 2.15 
Table 2.15: Primer sequences and annealing temperatures for gene sequencing and donor (dnr) 
template amplification. Restriction site tags for AvrII (orange) and BgIII (blue) are coloured. 










DBP1_M1 AAAAGATGGAGAACATAAAACTG N/A 
DBP1_M2 ATTATATATCAGAATTACCCATA N/A 











DBP2_M1 AAAAATAAAGTATGCGCAAATGAATGA N/A 
DBP2_M2 ATGGGGAAGGGATTATAT N/A 





2.7.3 Design of dbp1 and dbp2 donor templates 
Primers (Table 2.15) were designed to sequence and amplify the genomic DNA of P. 
cynomolgi Berok dbp1 and dbp2 genes. 
  
2.7.4 PCR amplification of dbp1 and dbp2 donor templates 
 Previously extracted (see 2.2.15) P. cynomolgi Berok DNA was amplified using the KAPA 
HiFi HotStart ReadyMixPCR Kit (Cat. No. 07958935001, Roche) according to the manufacturer’s 
instructions. In brief, for a 25 µL PCR, 25 ng of P. cynomolgi Berok DNA was mixed gently with the 
2X KAPA HiFi HotStart ReadyMix and 10 µM of the dbp1 and dbp2 donor template primers (Table 
 80 
2.15) individually. The PCR reaction was run through the kit specified thermocycler protocol. PCR 
products were run on a 1 % agarose gel (see 2.1.30) at 100 V for 90 minutes.  
 
2.7.5 Gel extraction of dbp1 and dbp2 donor templates  
Products run on 1 % agarose gel had their appropriate bands extracted using the Monarch Gel 
Extraction kit (Cat. No. T1020L, Monarch) as described in 2.5.10. The extracted product’s 
concentrations were measured using the ThermoScientificTM NanodropTM Spectrophotometer (Cat. 
No. 13400518, Fisher scientific). 
 
2.7.6 Approaches to restriction digest and sticky-end ligation of Donor template DBP1 and 
pDC2_vCAM_GFP_U6_hDHFR plasmid 
The dbp1 and the pDC2_vCam_GFP_U6_hDHFR plasmid were digested using BglII (Cat. No. 
R0144S, NEB) and AvrII (Cat. No. R0174S, NEB) restriction enzymes for 3 hours at 37 ºC. 
Variations of this protocol were performed to and are shown in Table 2.16. Changes were made to 
the insert:vector ratio, restriction enzyme units, heat inactivation of restriction enzymes, 
dephosphorylation of vector using CIP (Cat. No. M0290, NEB), mass of vector used in ligation, time 
and temperature of ligation, and inactivation of T4 DNA ligase (Cat. No. M0202L, NEB).  
 
2.7.7 Approaches to restriction digest and sticky-end ligation of Donor template DBP2 and 
pDC2_vCAM_GFP_U6_hDHFR plasmid 
The dbp2 and the pDC2_vCam_GFP_U6_hDHFR plasmid were digested using BglII and AvrII 
restriction enzymes for 3 hours at 37 ºC. Variations of this protocol were performed and are shown 
in Table 2.17. Changes were made to the insert:vector ratio, restriction enzyme units, heat inactivation 
of restriction enzymes, dephosphorylation of vector using CIP (Cat. No. M0290, NEB), mass of 
vector used in ligation, time and temperature of ligation, and inactivation of T4 DNA ligase (Cat. No. 






















1 3:1 0.75 units N Y 50 ng 16 ºC overnight N 
2 3:1 1 unit N Y 50 ng 16 ºC overnight N 
3 7:1 1 unit N Y 50 ng 16 ºC overnight N 
4 7:1 + 10:1 1 unit N N 50 ng 16 ºC overnight N 
5 3:1 + 7:1 1 unit N N 50 ng 1 hour (25 ºC) Y 
6 3:1 + 7:1 1 unit Y N 50 ng 1 hour (25 ºC) Y 
7 3:1 + 7:1 1 unit Y N 50 ng 16 ºC overnight Y 
8 3:1 + 7:1 1 unit N N 200 ng 16 ºC overnight N 
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1 3:1 0.75 units N Y 50 ng 16 ºC overnight N 
2 3:1 1 unit N Y 50 ng 16 ºC overnight N 
3 7:1 1 unit N Y 50 ng 16 ºC overnight N 




2.7.8 Transformation of protein localisation plasmids into DH5α E. coli (approach 1) 
 All ligation products were individually transformed into DH5α E. coli using a heat 
shock protocol as previously described in 2.6.5.  
 
2.7.9 Transformation of protein localisation plasmids into DH5α E. coli (approach 2) 
 All ligation products were individually transformed into DH5α E. coli using a heat 
shock protocol as described in 2.6.5, except SOCs media (see 2.1.24) was used instead of LB media 
(2.1.22).  
 
2.7.10 Colony PCR of protein localisation plasmids 
 A colony PCR master mix was prepared to include 2x OneTaqMasterMix (Cat. No. M0270, 
NEB) (see 2.1.32), and appropriate dbp gene primer pair (Table 2.15). A sterile pipette tip was 
touched to a single colony on transformation plates prepared in 2.7.10. A small ~1 cm line was 
streaked onto a new LB agar with ampicillin plate (see 2.1.26), and the residual bacteria on the pipette 
tip was swirled into the colony PCR master mix tube. Repeated for as many colonies as desired. Each 
sample was run through the kit specified thermocycler protocol. PCR products were run on a 1 % 
agarose gel (see 2.1.30) at 100 V for 90 minutes.  
 
2.7.11 Miniprep of protein localisation plasmids 
If the donor template was identified from colony PCR, the colony was incubated in 5 mL of 
LB broth with ampicillin (see 2.1.23) overnight shaking at 200 rpm at 37 ºC. Using the Monarch 
Plasmid Miniprep Kit (Cat. No. T1010L, Monarch), the plasmid DNA was extracted and purified 
from the E. coli as described in 2.5.6. The plasmid concentration was measured using the 
ThermoScientificTM NanodropTM Spectrophotometer (Cat. No. 13400518, Fisher scientific). 
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2.7.12 Sanger sequencing to confirm insert of donor template into 
pDC2_vCam_Cas9_U6_hDHFR plasmid 
Sanger sequencing was performed by the Genetic Analysis Services, Department of Anatomy, 
the University of Otago using the p7439, and dbp1 and dbp2 sequencing primers (Table 2.15) to 
check for insertion of donor templates into pDC2_vCam_GFP_U6_hDHFR plasmid. 
 
2.7.13 Maxiprep of complete GFP_DBP2 plasmid 
 The confirmed pDC2_vCam_GFP_U6_hDHFR_DBP2 plasmid was maxiprepped using the 
Macherey-Nagel Plasmid DNA purification kit NucleoBond Xtra Maxi Plus (Cat. No. 740416.50, 












CHAPTER 3 - RESULTS 
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3.1 Gene homology in Plasmodium species 
3.1.1 Introduction 
 The Y268S and K76T mutations in the cytb and crt genes respectively are known to cause 
drug resistance in P. falciparum (200). To our knowledge they have not yet been validated to cause 
drug resistance in P. vivax (187, 197).  
In P. falciparum, the Y268S mutation in the cytb gene has been validated to cause atovaquone (ATO) 
resistance (194). Cytb is involved in the electron transport chain of Plasmodium spp.’s mitochondria. 
The presence of this mutation reduces the number of hydrophobic contacts between ATO and cytb, 
forcing ATO to bind at locations distant from its active site.  
Similarly, for the P. falciparum crt gene, the K76T mutation has been validated as a cause of CQ 
resistance. The K76T mutation is located in a region of the protein that is predicted to be involved in 
substrate recognition. It removes a positive charge in the P. falciparum crt substrate binding site and 
allows CQ to be transported out of the digestive vacuole and away from its site of action(152-154).  
We chose to investigate whether these same mutations, once introduced into P. cynomolgi, would 
cause the same drug resistance, suggesting these mutations could cause the same drug resistance in 
P. vivax.  
In order to determine the likelihood of this correlation, we first investigated the specific gene 
homology between P. falciparum 3D7, P. vivax sal-1, P. cynomolgi B strain, and P. cynomolgi Berok.  
 
3.1.2 Highly conserved nucleotide and protein sequences of cytochrome b gene in Plasmodium 
P. falciparum 3D7, P. vivax sal-1, P. cynomolgi B strain, and P. cynomolgi Berok cytb nucleotide 
and protein sequences were aligned (Figure 3.1) and analysed by pairwise comparison (Table 3.1) to 
investigate the homology of the cytb gene across these species.  
Comparison of cytb between P. falciparum and P. vivax revealed the gene to be 87.4 % identical at a 
nucleotide level, and 91.0 % identical at the amino acid level. The lowest sequence homology 
identified was between P. falciparum 3D7 and P. cynomolgi Berok, with 87.3 % identity at the 
nucleotide level, and 91.0 % identity at the amino acid level. Between P. vivax and P. cynomolgi 
Berok, there was 98.9 % identity at the nucleotide level and 99.5 % identity at the amino acid level.  
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Identity was highest between P. cynomolgi B strain and P. cynomolgi Berok, with 99.1 % identity at 
the nucleotide level, and 99.7 % identity at the amino acid level. The site of the Y268S mutation is 
located at codon 268 (nucleotide 803) of the P. falciparum 3D7 sequence. There was a 100 % identity 
at codon 268 and nucleotide 803 between the four Plasmodium spp. (Figure 3.1).  
 
Table 3.1: cytb gene homology conserved across all four Plasmodium species.  Pairwise analysis 
of the cytb gene of multiple Plasmodium spp.. Nucleotide and protein sequence percentage (%) 
identity are shown in the table. Nucleotide % identity is shown in blue, and protein % identity is 
shown in orange. 




P. vivax Sal-1 




P. falciparum 3D7 - 91.0 % 91.2 % 91.0 % 
P. vivax Sal-1 87.4 % - 99.7 % 99.5 % 
P. cynomolgi B 
strain 
87.4 % 98.7 % - 99.7 % 
P. cynomolgi 
Berok 





Figure 3.1: 100 % identity conserved at Y268S mutation site across all four Plasmodium species. Clustal Omega alignment of the cytb gene A) nucleotide and 
B) protein sequences. Residue numbers are labeled according to the Plasmodium falciparum 3D7 sequence. The non-conserved residues are shaded grey, and the site 




3.1.3 Highly conserved nucleotide and protein sequences of chloroquine resistance transporter 
gene in Plasmodium.  
P. falciparum 3D7, P. vivax sal-1, P. cynomolgi B strain, and P. cynomologi Berok crt DNA, 
mRNA, and protein sequences were aligned (Figure 3.2) and analysed by pairwise comparison (Table 
3.2) to investigate the homology of the crt gene. Comparison of the crt gene between P. falciparum 
and P. vivax revealed the lowest % identity with, 43.0 % at the nucleotide level, 67.7 % at the 
transcript level, and 73.4 % at the amino acid level. Between P. vivax and P. cynomolgi Berok, there 
was 69.3 % identity at the nucleotide level, 91.9 % identity at the transcript level, and 94.6 % identity 
at the amino acid level. Identity was highest between P. cynomolgi B strain and P. cynomolgi Berok, 
with 83.1 % identity at the nucleotide level, 94.2 % identity at the transcript level, and 96.2 % identity 
at the amino acid level. The site of the K76T mutation is located at codon 76 (nucleotide 404) of the 
P. falciparum 3D7 sequence. There was a 100 % identity at codon 76 and nucleotide 404 between 
the four Plasmodium spp. (Figure 3.2).  
 
Table 3.2: crt gene homology conserved across all four Plasmodium species.  Pairwise analysis 
of the crt gene of multiple Plasmodium spp..   Nucleotide, mRNA, and protein sequence percent 
(%) identity are shown in the table. Nucleotide % identity is shown in blue, mRNA % identity is 
shown in green, and protein % identity is shown in orange. 




P. vivax Sal-1 






- 73.4 % 73.9 % 75.1 % 
P. vivax Sal-1 43.0 % 67.7 % - 92.5 % 94.6 % 
P. cynomolgi B 
strain 
46.3 % 70.1 % 65.6 % 91.5 % - 96.2 % 
P. cynomolgi 
Berok 





Figure 3.2: 100 % identity conserved at K76T mutation site across all four Plasmodium species. Clustal Omega alignment of the crt gene A) nucleotide B) mRNA, 
and C) protein sequences. Residue numbers are labeled according to the Plasmodium falciparum 3D7 sequence. The non-conserved residues are shaded grey, and the 





3.2 Optimising in vitro continuous culture of P. cynomolgi Berok 
3.2.1 Introduction 
 As described in Chapter 1, the lack of a continuous in vitro culture for P. vivax has hindered 
research around P. vivax invasion biology, and validation of molecular markers of drug resistance. 
To combat this, we proposed that P. cynomolgi Berok could be used as a model for P. vivax due to 
its genomic similarity, as well as its shared biological characteristics.  
A continuous culture method for P. cynomolgi has been established since the 1980s (90, 240). In 2019, 
Adeline Chua from our lab revised and optimised the culture methods for P. cynomolgi Berok (78). 
However, due to a need for non-human primate erythrocytes and serum, large and long-term culture 
remains expensive and difficult. We have sought to identify different serum combinations to reduce 
costs and thus allow for larger culture volumes to be maintained.  
Another challenge encountered has been loss of long-term cultures due to bacterial contamination. 
Following transfection, cultures are maintained for up to 2 months and so it is critical that these 
cultures do not become contaminated during this period of time.  To combat this, Peter Christensen 
(University of Otago, PhD student) investigated a range of antibiotic combinations that were effective 
in preventing bacterial contamination, while also not hindering the growth and survival of parasites. 
As part of the transfection process, it is necessary to enrich parasites at a late schizont stage. For the 
synchronisation of P. falciparum parasites, sorbitol is a cost-efficient compound that is regularly used 
to effectively kill off trophozoite and schizont populations, leaving synchronised populations of ring 
stage parasites (241, 242). However, as seen in P. knowlesi, sorbitol is relatively ineffective against most 
stages of P. cynomolgi Berok parasites, leaving them asynchronous after treatment. We investigated 
the efficiency of the compound Guanidine hydrochloride in synchronising P. cynomolgi parasites, as 
it has been shown to be effective with P. knowlesi parasites (243).  We also attempted to identify the 
time where treatment with these compounds would be most efficient. 
 
3.2.2 Serum 
 This work was done in collaboration with Kurt Ward (University of Otago, PhD student). 
Traditionally 20 % M. fascicularis serum was used to grow P. cynomolgi parasites, but the method 
developed by Chua et al. (2019) adapted the P. cynomolgi Berok strain to grow in 20 % foetal bovine 
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serum (FBS). These parasites shared similar morphological features to the their non-human primate 
(NHP) serum counterparts (244).   
In P. knowlesi, complete media made with 10 % horse serum and 10 % commercial serum substitute 
Albumax has become standard (245, 246).  In a search to find cheaper and more abundant serum for P. 
cynomolgi culture, we supplemented culture media with 20 % FBS, 10 % horse serum and 10 % 
Albumax, or 20 % NHP serum.  
Prior to this experiment all cultures were maintained on 20 % FBS media, as this was standard for 
the lab at the time. Media supplemented with either 20 % FBS, or 10 % horse serum and 10 % 
Albumax had reduced expansion rates compared to media supplemented with 20 % NHP serum 
(Figure 3.3). However, following day 2, 10 % horse serum and 10 % Albumax expanded more rapidly 
than 20 % FBS (Figure 3.3).  
Parasites in media supplemented with 10 % horse serum and 10 % Albumax were less 
morphologically distinct from 20 % NHP parasites, than those in 20 % FBS media (Figure 3.4). From 
this favourable parasite growth data, it was decided that 10 % horse serum and 10 % Albumax was a 
good substitute for 20 % NHP serum and this mix was used for all future routine culture. However, 
20 % NHP serum was still used occasionally for short term in vitro drug sensitivity assays, to ensure 






Figure 3.3: 10 % Horse serum + 10 % Albumax is a suitable serum alternative for P. cynomolgi in 
vitro culture. Effect of serum variations on P. cynomolgi Berok culture expansion rate as measured by flow 
cytometry. Cultures were sub-cultured on days four and eight. Work was done by Kurt Ward and Peter 
Christensen. 
 
Figure 3.4: 10 % horse serum + 10 % Ablumax adapted P. cynomolgi morphologically similar to 20 % 
non-human primate (NHP) P. cynomolgi. Comparative morphology of P. cynomolgi Berok when grown in 
media containing A) 20 % Non-human primate (NHP) serum, B) 20 % foetal bovine serum (FBS), or C) 10 
% horse serum and 10 % Albumax. Images in A) and B) were taken from Adeline Chua’s 2019 paper, and 
the image in C) were taken by Kurt Ward of parasites adapted to growth in 10 % horse serum and 10 % 
Albumax. Work was done by Kurt Ward and Peter Christensen. 
















10 % Horse serum + 10 % Albumax
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3.2.3 Synchronisation 
 In order to increase already very low transfection efficiencies of Plasmodium spp. using the 
Amaxa 4D Nucleofactor, parasites need to be enriched at the late schizont stage.  In past studies, 
magnetic-activated cell sorting (MACS) columns and percoll gradient centrifugation have been used 
to enrich P. cynomolgi Berok schizonts. However, these methods have significant drawbacks. MACS 
columns are good for enriching schizonts from small culture volumes, but the columns are very 
expensive. While percoll is useful for enriching schizonts from large culture volumes, it has shown 
to result in significant levels of infected RBC lysis. Given the importance of schizont enrichment for 
transfections in this project, Kurt Ward (University of Otago, PhD student) investigated the action of 
Nycodenz gradient centrifugation, commonly used for P. knowlesi schizont enrichment, as a possible 
alternative.  
The synchronisation of parasites can also be achieved at the ring stage. For this, sorbitol is commonly 
used for P. falciparum. Using sorbitol for P. cynomolgi at ring stage is relatively poor for 
synchronising parasites. However, guanidine hydrochloride (GuHCl) has been successful in the 
synchronisation of P. knowlesi parasites, so we compared the effectiveness of both sorbitol and 
GuHCl at killing parasites at specific stages of their blood stage life cycle.  
During routine culture it was recognised that neither sorbitol nor GuHCl were particularly effective 
at synchronising ring stage parasites, showing presence of schizonts after treatment. We therefore 
sought to investigate the optimal stage to target parasites with these treatments and determine which 
was the best compound for synchronising ring stage parasites. Treatment with GuHCl consistently 
had a higher reduction of parasitemia for all time points. Both compounds reduced the parasitemia of 
mid – late trophozoites and schizonts (Figure 3.5).  Although GuHCl appeared to be more effective 
at synchronising ring stage parasites, microscopy revealed that the difference between the treatment 
groups in Figure 3.5 was due to the elimination of all parasites when treated with GuHCl, with 
residual parasites looking unhealthy (Figure 3.6). Images taken of sorbitol treated cultures at the same 





Figure 3.5: Poor synchronisation of ring stage parasites following treatment with sorbitol or GuHCl. 
P. cynomolgi Berok parasites underwent our current optimal synchronisation protocol. P. cynomolgi 
schizonts were obtained using MACS. Schizonts were cultured on fresh M. fascicularis RBCs for 3 hours (to 
allow RBC invasion) then treated with sorbitol. Every 6 hours, separate cultures were treated with either 
sorbitol or GuHCl for 15 minutes at 37 ºC. 24 hours after the final treatment, the parasitemia (%) was 
measured for each culture using flow cytometry. The stages of parasite development are annotated as rings 
(0 – 8 hours), trophozoites (8 – 38 hours), and schizonts (36 – 48 hours). 
 
Figure 3.6: GuHCl has toxic effects on P. cynomolgi parasites. Comparative morphology of P. cynomolgi 
when treated with GuHCl or Sorbitol for synchronisation of ring stage parasites. Images were taken of P. 
cynomolgi parasites before and after treatments at 18 hours. 



















3.3 Construction of CRISPR plasmids 
3.3.1 Introduction 
 For most of this project the CRISPR cas9 plasmid design was based on Macus Lee’s (Fidock 
Lab) ‘one plasmid’ system (239). This plasmid contains the cas9 gene, a selection cassette, a gRNA 
insertion site, and a space for a repair template on a single plasmid. The Cas9 plasmid used was 
developed by Kurt Ward, and adapted from the Cas9 plasmids used in the Fidock lab (University of 
Columbia, USA) for P. falciparum transfections.   
At the beginning of this project, we did not have access to a published nor annotated P. cynomolgi 
Berok genome, and so primers were initially designed for P. cynomolgi B strain. While these genomes 
were very similar, we found substantial polymorphisms between Berok and the published B and M 
strains of P. cynomolgi.  Initial primers designed to amplify the cytb gene of P. cynomolgi Berok, 
were predicated upon P. cynomolgi B strain, and fortunately were able to amplify the gene of interest 
and allow for sequencing. Shortly after this, collaborator Pablo Biffani (National University of 
Singapore, Singapore) shared their (unpublished) whole sequencing of the P. cynomolgi Berok 
parasite and we confirmed our cytb sequence against the whole genome sequence.   
The production of the CRISPR plasmids containing my donor templates proved to be very 
challenging and only 4 plasmids of the 14 attempted were successfully constructed (2 cytb, 1 crt, and 
1 dbp2). Much of the project time was spent troubleshooting and trying to develop better methods for 
plasmid construction and cloning.  
As there is no published data on the in vitro transfection efficiency of P. cynomolgi (the only 2 
successful transfections in P. cynomolgi were episomal and, importantly, done in vivo), it was 
challenging to understand the level of transfection efficiency and where the possible failings in the 
method were occurring. Nonetheless I decided to try a second approach to the transfection of the crt 
gene. Crawford et al. (2017) successfully introduced drug resistance mutations into the P. falciparum 
parasite using a plasmid free method, utilising ssODNs, for CRISPR/Cas9 editing (247). I developed a 
method that combined Crawford et al (2017) and the ‘one plasmid’ system, where repair templates 





3.3.2 Construction of CRISPR plasmid targeting P. cynomolgi cytb 
Successful ligation of gRNAs 2 and 4 into the pDC2_vCam_Cas9_U6_hDHFR plasmid was 
achieved using sticky end ligation to produce the pDC2_vCam_Cas9_U6_hDHFR_gRNA2 and 
pDC2_vCam_Cas9_U6_hDHFR_gRNA4 plasmids respectively. Ligation of gRNAs 1 and 3 was 
unsuccessful. Sanger sequencing of the pDC2_vCam_Cas9_U6_hDHFR_gRNA3 and 







Figure 3.7: Successful insertion of gRNA 2 and 4 into Cas9 plasmid.  Sanger sequencing showing insertion of gRNA2 (purple highlight) and gRNA4 (blue 
highlight) into the pDC2 _vCam_Cas9_U6_hDHFR plasmid individually. Reference sequence is the undigested pDC2_vCam_Cas9_U6_hDHFR plasmid. The 




The cytb gene was successfully PCR amplified from P. cynomolgi Berok parasites. The repair 
template was successfully amplified from the extracted P. cynomolgi cytb gene. However, attempts 
at introducing DNA extracted cytb gene donor template by both blunt end ligation and sticky end 
ligation were unsuccessful.   
Sticky end ligation using a purchased cytb geneblock was successfully introduced into the 
intermediate vector, pGEM, to produce the pGEM_cytb plasmid (Figure 3.8 and Appendix 6). 
 
Figure 3.8: Successful production of pGEM_cytb plasmid. Gel electrophoresis showing successful 
ligation of the cytb gene donor template ligation into pGEM plasmid. Lane 1 1kb ladder (N3232L, NEB), 
lane 2 digested pGEM_cytb. pGEM plasmid (3 kb) and donor template (1.5 kb) extracted from lane 2. 
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Site directed mutagenesis (SDM) of the pGEM_cytb donor template to introduce BSMs for guides 4 
was successful producing the pGEM_cytb_BSM4 plasmid. The sequencing of the 
pGEM_cytb_BSM4 plasmid verified successful mutation (Figure 3.9). SDM to introduce the BSMs 
for gRNA 2 were unsuccessful.  
The Y268S mutation was not present in the wildtype P. cynomolgi Berok cytb gene (Figure 3.9).  Site 
directed mutagenesis of the pGEM_cytb_BSM4 donor template successfully introduced the Y286S 
mutation, producing the pGEM_cytb_Y268S_BSM4 plasmid. Sequencing of the 





Figure 3.9: Successful introduction of BSM4 and Y268S mutation into the cytb donor template.  Sequence alignment showing successful introduction of either 
both the Y268S and BSM4 mutations or the BSM4 mutation alone into the cytb donor template. Clustal Omega alignment of the wild type cytb gene in pGEM 
(pGEM_cytb), and pGEM_cytb_BSM4 and pGEM_cytb_Y268S_BSM4. The lower-case letters shaded grey show the introduced mutations in the donor templates. 




The individual donor templates containing either the Y268S mutation and BSM4, or the BSM4 alone 
were removed from pGEM by restriction digest and successfully inserted by sticky end ligation into 
the pDC2_vCam_Cas9_U6_hDHFR_gRNA4 plasmid to produce the final CRISPR plasmids 
pDC2_vCam_Cas9_U6_hDHFR_gRNA4_cytb_Y268S_BSM4 and 
pDC2_vCam_Cas9_U6_hDHFR_gRNA4_cytb_Y268S respectively. Sanger sequencing confirmed 
successful production of CRISPR plasmids (Appendix 11).  
 
3.3.3 Unsuccessful isolation of P. cynomolgi crt  
While successful ligation of gRNA2 into the pDC2_vCam_Cas9_U6_hDHFR plasmid was 
achieved using sticky end ligation to produce the pDC2_vCam_Cas9_U6_hDHFR_gRNA2 plasmid 
(Sanger sequencing of the pDC2_vCam_Cas9_U6_hDHFR_gRNA2 plasmid verified successful 
ligation (Figure 3.10)); the introduction of gRNA1 into the Cas9 plasmid was unsuccessful. 
The crt gene was initially isolated from the P. cynomolgi Berok DNA using primers tagged with 
restrictions sites for AatII and SfoI. Upon closer investigation, it was discovered that there was an 
AatII restriction site within the crt gene donor template (Figure 3.11). The crt donor template was 
then isolated using primers with restriction site tags for SfoI only.  
PCR amplification showed multiple off-target bands (Figure 3.12).  Gradient PCR with these primers 
offered no reduction off target bands (data not shown). Reducing P. cynomolgi Berok DNA, 
increasing primer concentrations, and decreasing extension times also offered no reduction of off-
target bands (data not shown).  
An attempt was made to gel extract the bands appearing at the correct band size (2389 basepairs), but 










Figure 3.10: Successful insertion of gRNA 2 into Cas9 plasmid.  Sanger sequencing showing insertion of gRNA2 (purple highlight) into the pDC2 
_vCam_Cas9_U6_hDHFR plasmid. Reference sequence is the undigested pDC2_vCam_Cas9_U6_hDHFR plasmid. The assembled sequence is the sequenced 








Figure 3.11: AatII restriction enzyme cut site present in crt gene. Diagram indicating the restriction 
enzyme cut sites when using A) donor primers 1 or B) donor primers 2. 
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Figure 3.12: Unsuccessful isolation of P. cynomolgi crt gene. Gel electrophoresis showing off-target 
amplification of P. cynomolgi Berok DNA when attempting to amplify the crt gene donor (DNR) template.  
Lane 1 1kb+ ladder (Cat. No. N0550L, NEB), lane 2 PCR amplified P. cynomolgi Berok DNA using DNR 
primers 1, and lane 3 PCR amplified P. cynomolgi Berok DNA using DNR primers 2. The crt product size 
was 2389bp. Products were run on a 1 % agarose gel at 80 Volts for 3 hours. 
 
Nested PCR was attempted to isolate the repair template but PCR amplification of the entire P. 
cynomolgi Berok crt gene also showed multiple off-target bands (Figure 3.13).   
In all cases we were unsuccessful in isolating the crt donor template. ssODNs were purchased.  
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Figure 3.13: Unsuccessful isolation of P. cynomolgi crt gene for nested PCR. Gel electrophoresis showing 
temperature gradient for nested PCR.  There were multiple off-target amplification of P. cynomolgi Berok 
DNA when attempting to amplify the crt gene donor (DNR) template.  Lane 1 1kb+ ladder (Cat. No. 
N0550L, NEB), lanes 2-8 gradient 53 ºC – 62 ºC using primers to amplify crt gene. The crt product size was 
5457 bp. Products were run on a 1 % agarose gel at 100 Volts for 90 minutes. 
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3.3.4 Construction of GFP plasmid for localisation of P. cynomolgi cytb DBP2 
 The dbp2 gene was successfully isolated from the P. cynomolgi Berok DNA using primers 
tagged with restrictions sites for BglII and AvrII.  
The first method of sticky end ligation of dbp2 was unsuccessful (see chapter 2).  
Different ligation ratios (insert:vector) of 3:1, 7:1, and 10:1 were used, with the 7:1 ratio successfully 
producing the GFP_DBP2 plasmid (Figure 3.14 and Appendix 12). 
 
Figure 3.14: Successful production of GFP_DBP2 plasmid. Gel electrophoresis showing successful 
ligation of the dbp2 gene into pDC2_vCAM_GFP_U6_hDHFR plasmid. Lane 1 1kb ladder (N3232L, NEB), 




3.3.5 Unsuccessful construction of GFP plasmid for localisation of P. cynomolgi cytb DBP1 
 The dbp1 gene was successfully isolated from the P. cynomolgi Berok DNA using primers 
tagged with restrictions sites for BglII and AvrII.  
The first method of sticky end ligation of dbp1 was unsuccessful (see chapter 2).  
Different ligation ratios of 3:1, 7:1, and 10:1 were unsuccessful (see chapter 2).  
Ligation with products that had undergone enzyme inactivation following the restriction was 
unsuccessful (see chapter 2).  
Changing to electroporation instead of heat shock transformation was unsuccessful (see chapter 2). 
Ligations at 3:1 and 7:1 ratio with 200 ng of vector DNA (instead of 50 ng) were unsuccessful (see 
chapter 2).  






3.4 Transfection of P. cynomolgi Berok  
3.4.1 Introduction 
 A total of 17 transfections of CRISPR cas9 plasmids were carried out during this study (Table 
3.3), with parasites returning in 5 cultures. However, none showed presence of genetic manipulation. 
Although this appears as an unsuccessful transfection method, another member of the lab (Kurt Ward, 
University of Otago, PhD student) has had 3 successful mutants reported (unpublished) via this 
method.  
2 transfections were undertaken using the low voltage/high capacitance method laid out by Fiddock 
and Wellems (1997) (248). This method was used prior to our use of antibiotics and when 20 % FBS 
was still being used. No parasites were observed in these transfections following drug pressure if they 
weren’t lost to contamination first.  
This method was replaced by the method described by Moon et al. (2013) with the Amaxa 4D 
Nucleofactor (97). Although parasites returned in 7 of the transfections, none were positive for 
mutations. 5 of these transfections are still currently being maintained and waiting for parasites.  






Culture end Reason or culture end 
1 - Y268S 1 Biorad 19.10.2019 25.11.2019 Contamination - bacteria 
2 - BSM4 1 Biorad 19.10.2019 02.12.2019 No parasites  
3 - Y268S 2 Amaxa 17.02.2020 02.04.2020 No parasites  
4 - BSM4 2 Amaxa 17.02.2020 23.03.2020 Contamination - bacteria 
5 - Y268S 3 Amaxa 08.06.2020 16.09.2020 
Parasites seen but no 
mutation 
6 - BSM4 3 Amaxa 08.06.2020 16.09.2020 
Parasites seen but no 
mutation 
7 - Y268S 4 Amaxa 27.07.2020 19.08.2020 Contamination - yeast 
8 - BSM4 4 Amaxa 27.07.2020 19.08.2020 Contamination - yeast 
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9 - Y268S 5 Amaxa 27.07.2020 19.08.2020 Contamination - yeast 
10 - BSM4 5 Amaxa 27.07.2020 07.10.2020 No parasites 
11 - Y268S 6 Amaxa 11.10.2020 03.12.2020 
Wild type parasites 
returned and population 
crashed 
12 - BSM4 6 Amaxa 11.10.2020 03.12.2020 
Wild type parasites 
returned and population 
crashed 
13- Y268S 7 Amaxa 11.10.2020 Still culturing 
Parasites have been seen 
but population crashed 
14 - BSM4 7 Amaxa 11.10.2020 Still culturing 
Parasites have been seen 
but population crashed 
15 - Y268S 8 Amaxa 21.12.2020 Still culturing  
16 - BSM4 8 Amaxa 21.12.2020 Still culturing  
17 - GFP_DBP2 Amaxa 21.12.2020 Still culturing  
 
3.4.2 Cytochrome B 
 Initially, it was expected that parasites would return in transfections after ~30 days, thus, for 
the first 4 transfections (if contamination didn’t cause prior failure) cultures were discarded if 
parasites were not observed after ~45 days. Transfections 5 and 6 were left for ~60 days before 
parasites were observed in culture. However, neither of these transfections showed integration of the 
Y268S mutation nor BSMs following sequencing.  
The next 11 transfections were all kept on WR99210 drug pressure indefinitely. 4 of these 
transfections were lost either to yeast contamination after ~20 days of culturing, or never showed 
parasites after ~3 months.  2 transfections came back (transfections 11 and 12) and were sequenced 
and returned negative for any mutations. A further 2 came back but suddenly crashed, and are still 
being cultured. In total there are currently 5 transfections being maintained.  
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For transfections 11-14, parasites were observed at ~ day 30, however, ~3 days later all culture 
populations crashed. This coincided with production of a new working stock of our selection drug 
WR99210.  
 
3.4.3 Chloroquine resistance transporter gene 
 The culture is currently being prepared for transfection of the 
CRT_pDC2_vCAM_Cas9_U6_hDHFR_gRNA2 and ssODN for gRNA2. We hope to transfect early 
March 2021. 
 
3.4.4 Duffy Binding Protein 2 
 Transfection of parasites with the GFP_DBP2 plasmid was performed on December 21st 2020 









CHAPTER 4 - DISCUSSION 
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4.1  Key findings 
4.1.1  Overview 
The development of a continuous in vitro culture method for P. falciparum in 1976, has led 
to enormous progress in understanding P. falciparum biology, including the understanding of P. 
falciparum invasion, as well as the investigation and validation of mutations associated with P. 
falciparum drug resistance (84, 88, 89). The continued lack of in vitro culture method for P. vivax has 
meant that the knowledge base for P. vivax has lagged behind P. falciparum in almost every aspect 
of its biology (10, 56, 99-102). To combat this, the sister taxon of P. vivax, P. cynomolgi, has been proposed 
as a viable and tractable model for P. vivax (50). The refinement of a continuous in vitro culture method 
for P. cynomolgi by Chua et al. (2019) has allowed for the genetic manipulation of P. cynomolgi to 
model potential drug resistance mutations in P. vivax and further our understanding of its invasion 
methods (78).  
In order to better understand the associations between specific mutations and reduced drug 
susceptibility, it is necessary to introduce these mutations into wildtype parasites and perform 
phenotypic assays to confirm whether these mutations are sufficient to cause drug resistance. Without 
an in vitro continuous culture method, reverse genetics cannot be performed and thus molecular 
markers for drug resistance in P. vivax cannot be validated.  Successful genetic manipulation of P. 
cynomolgi parasites with these suspected molecular markers of drug resistance will be absolutely 
critical to furthering our understanding of drug resistance in P. vivax, as well as help guide the 
development of drug regimens for P. vivax endemic countries.   
 
4.1.2 cytb gene homology  
  The P. vivax, P. knowlesi, and P. cynomolgi genomes have been previously compared by 
Tachibana et al. (2012), revealing ~90 % of genes to be orthologous between these three Plasmodium 
strains (50). The P. cynomolgi Berok strain genome sequence is not publicly available but was kindly 
shared with us by our collaborator Pablo Bafani (National University of Singapore, Singapore). The 
alignment (Figure 3.1) and pairwise comparison (Table 3.1) of P. falciparum 3D7, P. vivax sal-1, P. 
cynomolgi B strain, and P. cynomolgi Berok sequences suggested that the cytb gene was orthologous. 
For all four Plasmodium spp., nucleotide sequences had a lower % identity than protein sequences.  
This difference seems to indicate that, in this gene there was potential for variability in the nucleotide 
sequence between Plasmodium spp., while still maintaining increased protein homology. This 
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variability between nucleotide and protein sequence % identity has also been reported by Talundzic 
et al (2015) study comparing the k13 gene across several Plasmodium spp. In almost all cases, the % 
identity of k13 nucleotide sequences was lower than the % identity of the protein sequences, 
especially in coding regions of the gene (249).  
Investigation of cytb homology revealed P. falciparum 3D7 to be least homologous with the other 
species considered, with the nucleotide sequence having ~87 % identity, and the protein sequence 
having ~91 % identity. This was expected, because the P. vivax and P. cynomolgi strains are closer 
evolutionarily and genetically (Figure 4.1).   
The P. cynomolgi B strain currently serves as the reference genome for P. cynomolgi, as well as the 
draft genome for the assembly of the P. cynomolgi Berok strain (50, 250).  It was therefore expected that 
P. cynomolgi B strain and P. cynomolgi Berok would have the greatest % identity. Previous research 
comparing the mitochondrial DNA of several Plasmodium spp. (including P. falciparum 3D7, P. 
vivax sal-1, P. cynomolgi B strain, and P. cynomolgi Berok), indicated that the Berok strain of P. 
cynomolgi was the most genetically similar Plasmodium spp. to P. vivax (unpublished data provided 
by Singapore Immunology Network A*STAR as part of a MTA and RCA). Although this was also 
the case for the nucleotide sequence of the cytb gene, the protein sequence of P. cynomolgi B strain 
had greater % identity with P. vivax Sal-1 (99.7 %) than the P. cynomolgi Berok did (99.5 %). 
Examination of the specific amino residues that cause this difference in protein sequence % identity 
showed only one non-conserved residue at amino acid 120 of the P. cynomolgi B and P. cynomolgi 
Berok strains.  The P. cynomolgi B strain had a valine (V) where the P. cynomolgi Berok had an 
isoleucine (I). Although these are different amino acids, both have a non-polar and aliphatic R group 
and likely contribute the same function to the overall protein (251).  
The Y268S mutation in the cytb gene has been previously validated as a potential cause of atovaquone 
(ATO) resistance in P. falciparum (190-194, 252). It is unknown whether this same mutation confers ATO 
resistance in P. vivax or P. cynomolgi.  The alignment and comparison of nucleotide and protein 
sequences at the site of the Y268S mutation (nucleotide 803 and amino acid 268 of P. falciparum) 
revealed conservation of residues across all four Plasmodium spp. sequences (Table 3.1).  
Due to the observed sequence homology, it is possible that introducing the Y268S mutation into the 




4.1.3 crt gene homology 
To identify gene homology between P. falciparum, P. vivax, and P. cynomolgi, sequence 
alignments and pairwise comparisons of nucleotide, mRNA, and protein sequences were performed. 
The alignment (Figure 3.2) and pairwise comparison (Table 3.2) of P. falciparum 3D7, P. vivax sal-
1, P. cynomolgi B strain, and P. cynomolgi Berok sequences suggest that crt is orthologous across all 
four Plasmodium strains. Similar to the pairwise comparisons for cytb, there was a lower % identity 
of nucleotide sequences than protein sequences for all four Plasmodium spp..   
Investigation of crt homology revealed P. falciparum 3D7 to be least homologous, with nucleotide 
sequences having <48 % identity, mRNA sequences having <71 % identity, and protein sequences 
having <76 % identity. As shown in Figure 4.1, P. falciparum is genetically distant from P. vivax and 
P. cynomolgi strains.  Other phylogenetic analyses of Plasmodium spp. support the distant 
relationship of P. falciparum from P. vivax and P. cynomolgi strains (50, 253).  
As expected, P. cynomolgi B strain and P. cynomolgi Berok had the greatest % identity of nucleotide 
(83.1 %), mRNA (94.2 %), and protein (96.2 %) sequences. The P. cynomolgi Berok strain was the 
most genetically similar Plasmodium strain to P. vivax and was expected to have the highest 
nucleotide (69.3 %), mRNA (91.9 %), and protein (94.6 %) sequence % identity to P. vivax.  
The K76T mutation in the crt gene has previously been validated as a cause of chloroquine (CQ) 
resistance in P. falciparum (148-151).  The P. vivax crt gene has recently been linked to CQ resistance, 
but the K76T mutation has not been validated as a cause of CQ resistance in P. vivax (254). The 
alignment and comparison of nucleotide and protein sequences at the site of the K76T mutation 
(nucleotide 404 and amino acid 76 of P. falciparum) revealed conservation of residues across all four 
Plasmodium spp. sequences.  
Due to the observed sequence homology, it is possible that introducing the K76T mutation into the 
P. cynomolgi Berok genome would result in the same drug resistance that has been seen/validated in 
P. falciparum as a way of modelling CQ resistance in P. vivax. However, it has been reported that 
the wild-type P. vivax crt gene is capable of CQ transport, whereas wild-type P. falciparum can only 
transport CQ when it harbours specific mutations such as K76T (156). Investigation into whether 
expression of multiple copies of the crt gene in P. cynomolgi would have the same effect would be a 
particularly fascinating project in the future. For P. knowlesi the p230p gene has been shown to be 
non-essential during the blood stage and is routinely used as a site to introduce transgenes (255, 256). It 
would be interesting to see if it was possible to introduce multiple copies of the wildtype crt gene 





Figure 4.1: Plasmodium cynomolgi Berok is phylogenetically closest to P. vivax. RaXML tree using the complete mitochondrial genome from Plasmodium spp. 
(unpublished data provided by Singapore Immunology Network A*STAR as part of a MTA and RCA). Please note that the clone used in our study (P. cynomolgi 




P. vivax & P. simium clade
P. cynomology Berok A7
P. cynomology M strain
Other P. cynomology isolates (Nada 
Raja et al 2016 BMC Evol Bio)
RaXML tree using complete mitochondrial genome from other Plasmodium spp. 
• P. cynomology BA7 clusters separated from any other P. cynomology sample sequenced and shows a genetic distance 
to other P. cynomology isolates similar to P. vivax mitochondrial genome.




4.1.4 Production of the cytb CRISPR plasmid 
 The pDC2_vCam_Cas9_U6_hDHFR plasmid is large (~12 kb), so initial cloning steps were 
performed in the smaller (3 kb) plasmid, pGEM, to reduce the likelihood of transcription error during 
site directed mutagenesis (SDM) (257). Ligation of both the extracted cytb gene and the geneblock into 
pGEM by TA cloning was unsuccessful. Blunt-end ligations are challenging to perform and can be 
up to 100 times less efficient than sticky-end ligation. As is common for most cloning methods, larger 
DNA fragments will typically insert with lower efficiency. Blunt-end ligation often results in inserts 
being incorporated in the wrong orientation or in empty vectors where there is re-circularisation of 
plasmids. These challenges can be reduced, but not eliminated (258).  
Subsequently, sticky-end ligation was used to ligate the cytb geneblock with the cloning vector pGEM 
to successfully produce the pGEM_cytb plasmid. During the cloning of the cytb gene into pGEM, 
there was a low efficiency of successful clones (12.5 %), which could be attributed to the relatively 
high A+T content (74.54 %) of the P. cynomolgi Berok cytb gene. Plasmodium spp. are known to 
exhibit high A+T content, with the highest A+T content being seen in P. falciparum (80.6 %) and a 
lower A+T content (<60 %) in the sister species P. vivax (259).  The high A+T content has led to 
difficulty in other cloning studies involving Plasmodium spp., preventing the construction of large 
DNA inserts due to its instability in E. coli (207, 260-262).  Shorter donor template sequences have been 
proposed to be more efficient; however, Mohring et al. (2019) reported that longer regions of 
homology increase integration efficacy. It was therefore decided that it would be optimal to use 
template sequences >800 bp in length (256).  The existence of multiple repeat sequences within the 
cytb gene could have led to self-ligation or ligation with pGEM at an unexpected region of the donor 
template.  
In the future I would like to investigate using an alternative intermediate vector to pGEM for cloning 
of P. cynomolgi genes.  The pJAZZ vector designed by Godiska et al (2010), is a cloning vector for 
E. coli capable of cloning 0 – 30 kilobase (kb) inserts, particularly capable of maintaining inserts 
from very A+T rich genomes. In their work, they were able maintain 2 – 4 kb inserts from Piromyces, 
which has an A+T content of up to 96 %.  With our inserts typically only ranging from 0.8 – 2 kb, 
and with a A+T content of 74.54 % for P. cynomolgi, this could yield greater success with our cloning.   
There was successful production of 2 complete CRISPR plasmids; 
hDHFR_gRNA4_cytb_Y268S_BSM4 and pDC2_vCam_Cas9_U6_hDHFR_gRNA4_cytb_Y268S. 
Our collaborators Vipin and Pablo Bifani (University of Singapore, Singapore) kindly gifted us a list 
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of potential gRNAs that target the cytb gene. Although we aimed to pick gRNAs with the highest 
efficiency, we also required them to be within 100 – 200 bp of the site for point mutation (256, 263). Out 
of all the gRNAs we were provided, the highest efficiency was ~0.5/1, however this particular gRNA 
was 586 bp away from our target site  and thus not used (264). Because there was low efficiency 
associated with gRNA 4 (0.15), we tried to produce more plasmids with 3 different gRNAs, but had 
limited success. Another consequence of Plasmodium spp.’s A+T rich genome is that there is 
increased potential for poly-T stretches within gRNA sequences, and therefore premature 
termination. RNA polymerases use these poly-T stretches to signal termination when expressing 
small RNAs (263, 265).  
The enzyme chosen to digest our Cas9 plasmid, BbsI, was not sensitive to methylation, and thus it is 
unlikely that failure to insert the gRNAs 1 and 3 (for cytb) in to the Cas9 plasmid was due to this.  
The cloning of these gRNAs was only performed using TOP10 E. coli, and therefore it would be 
beneficial to re-attempt these ligations using the electrocompetent and chemically competent DH5α 
E. coli. It is hypothesised that the trouble cloning Plasmodium spp. genes is due to inherent low 
efficiency when performing these ligations, and not the use of low copy plasmids. If we are to 
continue to use this one plasmid system for our transfections of P. cynomolgi, it would be worth 
trying to reduce our cas9 plasmid’s size, as large plasmids have been reported to reduce cloning 
efficiency (266).   
We were able to successfully insert gRNA2 into the cas9 plasmid, however, we were unable to 
introduce the BSMs for gRNA2 into the repair template. There was no production of colonies on LB 
agar with ampicillin following SDM. Considering there had previously been success using the same 
protocols, primers, and reagents, it was interesting that this SDM failed. There were a number of 
potential contributors to this issue; including the possibility that the DpnI enzyme degraded due to 
cold chain issues identified by the laboratory manager late in the project. This could have led to the 
deterioration of the enzyme making it inefficient during SDMs. However, we tried using double the 
suggested units of DpnI and redid work with newly bought DpnI enzyme, both of which still didn’t 
yield colonies. We also discovered that the competent DH5α that was being used had an efficiency 
of ~ 1 x104 CFU/µg, when it should ideally have been ~ 1 x109 CFU/µg. Due to time restraints these 





4.1.5 Production of the crt CRISPR plasmid 
 When trying to PCR amplify the crt gene from P. cynomolgi Berok DNA, primers designed 
were amplifying non-specifically and we were unable to successfully isolate the crt gene from P. 
cynomolgi Berok DNA. A number of method variations were attempted including increasing and 
decreasing DNA concentrations, gradient PCR to optimise annealing temperatures, increasing primer 
concentrations, and decreasing the extension time during PCR. In all cases there was still a large 
amount of non-specific amplification (Figure 3.12) and when bands at the correct band size were gel 
extracted, Sanger sequencing indicated that this was not the P. cynomolgi crt gene. At this stage we 
are unsure what DNA was in these bands. It is likely that the primers have non-specifically amplified 
other areas of P. cynomolgi Berok DNA. Primers were checked using the NCBI database to check 
for primer specificity and showed no indication of targeting elsewhere. However, the P. cynomolgi 
Berok genome sequence is not currently publicly available and therefore we could only compare with 
P. cynomolgi B and M strains. 
After discovering the presence of the AatII restriction site within the crt gene our options were limited 
as to what alternative restriction site could be used for ligating the crt repair template with the 
intermediate cloning vector pGEM. Due to our limited array of enzymes and time restrictions, we 
were left with the option of having SfoI cut sites at both ends of the repair template. This would have 
had additional complications if PCR had been successful, because we would have had to use TA 
cloning to insert the gene into the pGEM plasmid as we did not have a linearised pGEM plasmid with 
SfoI restriction sites at both ends (only pGEm plasmids with an SfoI and AatII tag).   
While troubleshooting the PCR amplification of the crt gene from P. cynomolgi genomic DNA, I 
discovered that for studies investigating the crt gene, complementary DNA (cDNA) was often used. 
However, for the genetic manipulation we are attempting, we require the genomic DNA (gDNA) 
sequence as the repair template, otherwise the parasite genome will not repair correctly. In studies 
where gDNA was used, it was typically isolated using nested PCR, something that could have been 
investigated further in this study (200, 267, 268).  We considered designing an entirely new set of primers 
for the amplification of this gene both through direct amplification and through nested PCR but due 
to time constraints and a desire to investigate different transfection methods for P. cynomolgi, we 
decided to purchase ssODNs rather than continue troubleshooting the PCR amplification of the crt 
gene. In the future it would be worthwhile pursuing this further in an attempt to produce the plasmid 
as part of the ‘one plasmid’ system and compare the two transfection methods.  
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As previously mentioned, shorter repair templates have been proposed to be more efficient. For our 
one plasmid system it appears that the optimal length of repair DNA is ~800 bp (as discussed in 
4.1.4). It has been reported that repair templates as small as 200 bp have successfully introduced 
mutations into P. falciparum (247).  This specific work was performed by Crawford et al (2017) using 
ssODNs in a ‘plasmid-free’ protocol. From this study we decided that we would attempt a modified 
protocol for transfection using ssODNs.  
4.1.6 Production of the dbp1 and dbp2 GFP plasmids 
 The pDC2_vCAM_GFP_U6_hDHFR plasmid used by our lab has previously been 
successfully transfected into P. cynomolgi Berok parasites to produce fluorescent parasites. In order 
to localise the invasion proteins dbp1 and dbp2 we aimed to modify the GFP plasmid to individually 
tag the proteins for visualisation via microscopy (269). Despite multiple attempts and multiple methods, 
we were unsuccessful in producing a GFP plasmid containing the dbp1 gene.  
A number of variations of our restriction cloning methods were attempted including inactivation of 
enzymes during restriction digest, trying different insert:vector ratios during ligation, trying different 
transformation techniques (heat shock, and electroporation), trying different competent bacteria, 
trying both overnight and 1 hour ligation protocols, inactivating ligation enzymes, increasing the 
regeneration time during bacterial transformation, and increasing the concentration of digested 
plasmid backbone (and thus insert) during ligation.  
Plasmodium spp. as a whole are notoriously difficult to clone. As we’ve seen for the cloning of cytb, 
there are typically low efficiencies associated with cloning Plasmodium spp. As a positive control 
during transformation, we would transform undigested GFP plasmid. The GFP plasmid is a low copy 
plasmid, which could be contributing to low efficiency seen with the cloning of P. cynomolgi genes. 
However, as mentioned in 4.1.4, the competent bacteria being used was not as efficient as it should 
have been. Redoing all this work in confirmed highly competent bacteria is a crucial step to take place 
in the future.  
We were successfully able to clone dbp2 into the GFP plasmid but, as seen with cytb, there was a 
very low efficiency, with only 1 of 24 colonies presenting as positive. There is the possibility that the 
T4 ligase enzyme being used was faulty, likely due to excessive freeze thaw, or not being kept on ice 
during use. However, a new T4 ligase enzyme from Promega was used and trialled using both the 
NEB and Promega protocols with different insert:vector ratios, with no success for dbp1.  
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It has become increasingly obvious throughout this study that the cloning of P. cynomolgi is difficult. 
Collaborators have expressed their own difficulties when attempting cloning of other P. cynomolgi 
genes. However, this cloning should not be impossible. In our work, this process has been very 
inefficient and further investigation to effectively troubleshoot these protocols needs to be undertaken 
including the replacement of reagents.  
 
4.1.7 Synchronisation of P. cynomolgi 
 The enrichment of parasites at the ring stage is crucial to the performance drug assays and, 
most importantly, transfections. Laboratories that work with P. falciparum report great success with 
the use of sorbitol as a compound to synchronise parasites at the ring stage (270). The use of sorbitol 
for P. cynomolgi Berok however has limited efficacy. This is also the case for P. knowlesi, which led 
to the discovery of GuHCl, which enables efficient synchronisation of P. knowlesi parasites at ring 
stage (243, 271).  
Our optimal synchronisation technique currently involves separating schizonts from an already 
synchronous P. cynomolgi culture using magnetic-activated cell sorting (MACS). Although more 
effective than sorbitol alone, MACS is a costly procedure and for the volumes of culture we seek to 
synchronise, a single column is not sufficient.  These schizonts are then cultured on uninfected M. 
fascicularis RBCs for 3 hours (allowing schizonts to release merozoites which will invade RBCs), 
and then treated with sorbitol to try remove any remaining schizonts.  
The results shown in Figure 3.5 initially seem to suggest that GuHCl was more effective than sorbitol 
at synchronising P. cynomolgi parasites because there was a larger decrease in parasitemia. However, 
because these parasites were predominantly at ring stage from hours 0 – 8, the reduction in 
parasitemia was a reduction of total parasitemia rather than a result of removing any schizonts that 
persisted through the initial sorbitol treatment. Examination of slides taken after each 6-hour 
treatment interval, showed that GuHCl had toxic effects on parasites with visual signs of necrosis 
(Figure 3.6). It is important to note that when viewing the thin smears taken after GuHCl treatment, 
it was difficult to find parasites in all slides. In future experiments we suggest thick smears would be 
more sensitive in detecting ‘sick’ parasites. The mechanism of GuHCl toxicity is currently unknown 
for Plasmodium spp. with the exception of  P. knowlesi (243). As GuHCl has been used for denaturing 
P. falciparum parasitophorous vacuolar protein 1, it can be hypothesised that GuHCl is affecting 
critical P. cynomolgi fitness (272).  
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Because our transfections require large volume synchronous cultures, it would be inefficient to use 
GuHCl as there is such a significant drop in parasitemia following GuHCl treatment, cultures would 
need to undergo 1 – 2 erythrocytic cycles before they reach a suitable parasitemia for transfection, at 
which point the culture will likely have become asynchronous again.  
In the future I would like to pursue this work further and examine how the parasites recover, and how 
their growth and development may be affected by GuHCl treatment. If GuHCl is having toxic effects 
on P. cynomolgi culture, it would be interesting to see whether this would lead to further 
asynchronicity as individual parasites may recover at different rates.  
For now, although inefficient, sorbitol will continue to be used as our predominant method for 
synchronisation of P. cynomolgi parasites as it is a cost-efficient method that is able to increase culture 
synchronicity while not compromising parasite health.  
 
4.1.8 Transfection of P. cynomolgi 
 In 2019, Kurt Ward (University of Otago, PhD student) successfully produced the first 
episomal transfection for in vitro P. cynomolgi culture. In 2020 he successfully introduced the 
putative drug resistance marker mdr1 Y976F, and the silent BSM in PcBerdhfr (273). His work 
introducing these drug resistance markers, are the first ever record of integrative genetic manipulation 
of this species. Despite this, transfection of P. cynomolgi is still the biggest barrier yet to be efficiently 
overcome by our laboratory. Throughout this study the transfection process used by our lab has been 
optimised, but as is the case for all Plasmodium spp., is still not efficient. Notably the only two other 
transfections of P. cynomolgi have been performed in vivo and were episomal rather than integrative, 
limiting our ability to compare transfection techniques/efficiencies with these earlier studies (216, 217).  
Our current transfection protocol for P. cynomolgi Berok is based on protocols used by the Fiddock 
lab (University of Columbia, USA), whose focus is on the manipulation of P. falciparum. By working 
with the human parasite P. falciparum, they have access to abundant and accessible human RBCs, 
and are therefore able to increase their transfection efficiencies by using much larger culture volumes. 
This is not currently an option for P. cynomolgi transfection, as M. fascicularis RBCs and serum is 
expensive and limited.  
Both successful transfections from Kurt Ward’s work were performed using the Amaxa 4D 
Nucleofactor. These same methodologies have been used in the transfection of all the plasmids 
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produced in this study. To date, this project has only had 17 attempts at transfection, compared to 
Kurt Wards work where there was a total of 46 transfections performed.  Furthermore, of my 17 
attempts, only the last 5 attempts did not have complications due to contamination, poor drug efficacy, 
or early culture termination.  
The contamination of these long-term cultures was a huge roadblock for this project, as these cultures 
can take up to 70 days to show parasites and were regularly getting contaminated around days 30–
40. Routine in vitro cvulture of P. falciparum uses Gentamicin to control bacterial contamination. 
However for p. cynomolgi, this results in parasite death. Work done by Peter Christenson (University 
of Otago, PhD student), to develop an antibiotic combination safe for use in our P. cynomolgi cultures, 
was crucial to the progress of this work.  The addition of 25 µg/mL penicillin and 0.5 µg/mL 
cefquinome did not inhibit the development of healthy parasites. Following his work, P. cynomolgi 
culture media containing penicillin and cefquinome was used for long term culture maintenance of 
Plasmodium cynomolgi with significantly reduced instances of contamination.  
Early termination of cultures was in hindsight a major error. We were initially comparing recovery 
times with other Plasmodium spp. such as P. falciparum and P. knowlesi, whose blood stage life cycle 
is half the time of P. cynomolgi. We should have instead been expecting the cultures to come back 
closer to 60+ days rather than 30 days. For the later transfections performed, we kept cultures 
indefinitely unless there was contamination, or they were harvested to make stocks when parasites 
were seen.   
Transfections 11 – 14 returned parasites while maintained on WR99210 drug pressure indefinitely. 
However, after extraction and sequencing of this DNA, parasites were reported to be wildtype. 
Interestingly, just a few days after parasites were first observed in the cultures, a new batch of working 
stock WR99210 was produced, and within the following week all parasites from all transfections 
disappeared. Therefore, we determined that it was likely that the drug working stock had undergone 
too many freeze/thaw cycles and lost its effectiveness. Subsequently, WR99210 working stock has 
been aliquoted into individual Eppendorf’s to prevent this issue in future work. 
From the 14.12.2020 to the 20.01.2021 we did not have access to our normal trimix gas for culture 
chambers (due to shipment delays associated with COVID) and so the candle jar method was used. 
Other members of the laboratory maintaining cultures at ~ 3-10 % parasitaemia noticed that cultures 
crashed and grew much more slowly when candle jar was implemented. There is a potential that this 
could have disturbed the recovery and growth of transfected cultures (transfections 13-16) but 
cultures will be maintained regardless in case there was no effect.  
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Although working with P. cynomolgi has meant that we cannot easily compare and contrast current 
successful transfections techniques used for P. cynomolgi, we ultimately have the ability to trial 
multiple different transfection methods used for other Plasmodium spp., and regardless of the 
outcome these will likely yield interesting results. There are endless opportunities for this work in P. 
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CHAPTER 6 - APPENDIX  
 140 
































Appendix 2: ssODN for crt gene. K76T mutation highlighted yellow, lowercase and bolded. BSM 







Appendix 3: ssODN for crt gene. K76T mutation highlighted yellow, lowercase and bolded. BSM 










Appendix 4: Full multiple gene alignment of P. falciparum 3D7, P. vivax sal-1, P. cynomolgi B 





Appendix 5: Full multiple gene alignment of P. falciparum 3D7, P. vivax sal-1, P. cynomolgi B 
strain, and P. cynomolgi Berok cytb protein sequences.
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Appendix 7: Full sequence assembly of pGEM_cytb_Y268S_BSM4 using the cytb geneblock as a 
reference. Non-conserved residues (the BSMs) are coloured blue, and the Y268S mutation is 




Appendix 8: Full multiple gene alignment of P. falciparum 3D7, P. vivax sal-1, P. cynomolgi B 








Appendix 9: Full multiple gene alignment of P. falciparum 3D7, P. vivax sal-1, P. cynomolgi B 












Appendix 10: Full multiple gene alignment of P. falciparum 3D7, P. vivax sal-1, P. cynomolgi B 
strain, and P. cynomolgi Berok crt protein sequence. 
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Project: GFP_DBP2 seq.sqd Restriction 1 Restriction Clone 1
3,090 3,100 3,110 3,120 3,130
TATTAATATTTCTATCAACTGTACCAGTAGCATCGCCCGTAGCAGAGCT
TATTAATATTTCTATCAACTGTACCAGTAGCATCGCCCGTAGCAGAGCTRestriction 1 Restriction Clone 1
TATTAATATTTCTATCAACTGTACCAGTAGCATCGCCCGTAGCAGAGCTGFP_DBP2_M3.ab1(23>812)
ACCAGTAGCATCGCCCGTAGCAGAGCTGFP_DBP2_M2.ab1(25>972)
3,140 3,150 3,160 3,170 3,180
TGTATTATCTGAAGTATTACTACTATCTTTAGTAGCCTTCGCCTTATCA
TGTATTATCTGAAGTATTACTACTATCTTTAGTAGCCTTCGCCTTATCARestriction 1 Restriction Clone 1
TGTATTATCTGAAGTATTACTACTATCTGFP_DBP2_M3.ab1(23>812)
TGTATTATCTGAAGTATTACTACTATCTTTAGTAGCCTTCGCCTTATCAGFP_DBP2_M2.ab1(25>972)
3,190 3,200 3,210 3,220 3,230
TTGTCTTGCCGCATTTCCGTCTCACCTTTACTATTTGAATCAGGAATAG
TTGTCTTGCCGCATTTCCGTCTCACCTTTACTATTTGAATCAGGAATAGRestriction 1 Restriction Clone 1
TTGTCTTGCCGCATTTCCGTCTCACCTTTACTATTTGAATCAGGAATAGGFP_DBP2_M2.ab1(25>972)
3,240 3,250 3,260 3,270 3,280
CCATTGATTCCTTAGATTCCGTAGATCCATTGTTATCACTATTATCTTT
CCATTGATTCCTTAGATTCCGTAGATCCATTGTTATCACTATTATCTTTRestriction 1 Restriction Clone 1
CCATTGATTCCTTAGATTCCGTAGATCCATTGTTATCACTATTATCTTTGFP_DBP2_M2.ab1(25>972)
3,290 3,300 3,310 3,320 3,330
CGAAGGCCCCAAACCTTTATGGGTAGTTACCAATGAGTTTTCACTATTT
CGAAGGCCCCAAACCTTTATGGGTAGTTACCAATGAGTTTTCACTATTTRestriction 1 Restriction Clone 1
CGAAGGCCCCAAACCTTTATGGGTAGTTACCAATGAGTTTTCACTATTTGFP_DBP2_M2.ab1(25>972)
3,340 3,350 3,360 3,370 3,380
TTTACAGGTATATATGCACTGTTCACAGTACCATCACCTGCGCTATATG
TTTACAGGTATATATGCACTGTTCACAGTACCATCACCTGCGCTATATGRestriction 1 Restriction Clone 1
TTTACAGGTATATATGCACTGTTCACAGTACCATCACCTGCGCTATATGGFP_DBP2_M2.ab1(25>972)
3,390 3,400 3,410 3,420 3,430
CTTCAACAGTAGACTCAGAAGGTCGACCATTTAATGTGCCTAAGTTTTC
CTTCAACAGTAGACTCAGAAGGTCGACCATTTAATGTGCCTAAGTTTTCRestriction 1 Restriction Clone 1
CTTCAACAGTAGACTCAGAAGGTCGACCATTTAATGTGCCTAAGTTTTCGFP_DBP2_M2.ab1(25>972)
3,440 3,450 3,460 3,470
CTTTCCAGCTTCTGCAATGCTTGTAACGCTCGTAGTGTCGTCCCTCCTT
CTTTCCAGCTTCTGCAATGCTTGTAACGCTCGTAGTGTCGTCCCTCCTTRestriction 1 Restriction Clone 1
CTTTCCAGCTTCTGCAATGCTTGTAACGCTCGTAGTGTCGTCCCTCCTTGFP_DBP2_M2.ab1(25>972)
3,480 3,490 3,500 3,510 3,520
TCACTTACATATTTCTGCGGGTCAACATTTTTAGCACTTGCACTTTCAG
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3,530 3,540 3,550 3,560 3,570
GAATATCACTTCGCTGTACATTGCTTTTTTCAGGTGTCTGATTTCCATT
GAATATCACTTCGCTGTACATTGCTTTTTTCAGGTGTCTGATTTCCATTRestriction 1 Restriction Clone 1
GAATATCACTTCGCTGTACATTGCTTTTTTCAGGTGTCTGATTTCCATTGFP_DBP2_M2.ab1(25>972)
3,580 3,590 3,600 3,610 3,620
TTGACCATTCCCCGTAACAGCTTTACCTGTGGTAGAATTATGTGCGCCA
TTGACCATTCCCCGTAACAGCTTTACCTGTGGTAGAATTATGTGCGCCARestriction 1 Restriction Clone 1
TTGACCATTCCCCGTAACAGCTTTACCTGTGGTAGAATTATGTGCGCCAGFP_DBP2_M2.ab1(25>972)
3,630 3,640 3,650 3,660 3,670
CTGTTAATATTTCCATGCGCAGAATCTCCTTGAACCTTCTTCTCCTTAC
CTGTTAATATTTCCATGCGCAGAATCTCCTTGAACCTTCTTCTCCTTACRestriction 1 Restriction Clone 1
CTGTTAATATTTCCATGCGCAGAATCTCCTTGAACCTTCTTCTCCTTACGFP_DBP2_M2.ab1(25>972)
3,680 3,690 3,700 3,710 3,720
TGCTATCTACAGCCTGAATTTTCGGATTCGAAATTGGTGCCTTAGATTC
TGCTATCTACAGCCTGAATTTTCGGATTCGAAATTGGTGCCTTAGATTCRestriction 1 Restriction Clone 1
TGCTATCTACAGCCTGAATTTTCGGATTCGAAATTGGTGCCTTAGATTCGFP_DBP2_M2.ab1(25>972)
3,730 3,740 3,750 3,760 3,770
AGCAGCATTTTCTACATTTGTTACGACTTTCTGAGTATTTTTTTTAACG
AGCAGCATTTTCTACATTTGTTACGACTTTCTGAGTATTTTTTTTAACGRestriction 1 Restriction Clone 1
AGCAGCATTTTCTACATTTGTTACGACTTTCTGAGTATTTTTTTTAACGGFP_DBP2_M2.ab1(25>972)
3,780 3,790 3,800 3,810 3,820
GTACAAACGCATAAATCAATATATGCATTATCACGTTGGTTAATTTCAT
GTACAAACGCATAAATCAATATATGCATTATCACGTTGGTTAATTTCATRestriction 1 Restriction Clone 1
GTACAAACGCATAAATCAATATATGCATTATCACGTTGGTTAATTTCATGFP_DBP2_M2.ab1(25>972)
3,830 3,840 3,850 3,860 3,870
TCTCAAAAGCCACCTCGTTAAATCCATCTAACTCCTGTTTTAGTATATC
TCTCAAAAGCCACCTCGTTAAATCCATCTAACTCCTGTTTTAGTATATCRestriction 1 Restriction Clone 1
TCTCAAAAGCCACCTCGTTAAATCCATCTAACTCCTGTTTTAGTATATCGFP_DBP2_M2.ab1(25>972)
3,880 3,890 3,900 3,910 3,920
ATAAGCAGTTACGATATCTGCCGTCTCGATGTTTTGTACTTTTTTTACA
ATAAGCAGTTACGATATCTGCCGTCTCGATGTTTTGTACTTTTTTTACARestriction 1 Restriction Clone 1
ATAAGCAGTTACGATATCTGCCGTCTCGATGTTTTGTACTTTTTTTACAGFP_DBP2_M2.ab1(25>972)
3,930 3,940 3,950 3,960
CTTTTGAATTTATTTGACAGAACATCCCATTGTTTTTTTTTTCTGGTTA
CTTTTGAATTTATTTGACAGAACATCCCATTGTTTTTTTTTTCTGGTTARestriction 1 Restriction Clone 1
CTTTTGAATTTATTTGACAGAACATCCCATTGTTTTTTTTTTCTGGTTAGFP_DBP2_M2.ab1(25>972)
3,970 3,980 3,990 4,000 4,010
TCCATTGATCATATAATATACACGCATTTTTACATGGAAGTACCGTACA
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4,020 4,030 4,040 4,050 4,060
TACTTTTATATCAGTATAATAGAATTTTCTATCACATTTTTCTTTCAGT
TACTTTTATATCAGTATAATAGAATTTTCTATCACATTTTTCTTTCAGTRestriction 1 Restriction Clone 1
TACTTTTATATCAGTATAATAGAATTTTCTATCACATTTGFP_DBP2_M2.ab1(25>972)
TACTTTTATATCAGTATAATAGAATTTTCTATCACATTTTTCTTTCAGTGFP_DBP2_M1.ab1(20>990)
4,070 4,080 4,090 4,100 4,110
TTTTGCAGTTCTTTGGGTAATTCTGATATATAATCCCTTCCCCATTCTC
TTTTGCAGTTCTTTGGGTAATTCTGATATATAATCCCTTCCCCATTCTCRestriction 1 Restriction Clone 1
TTTTGCAGTTCTTTGGGTAATTCTGATATATAATCCCTTCCCCATTCTCGFP_DBP2_M1.ab1(20>990)
4,120 4,130 4,140 4,150 4,160
GAATCCATCTATATATCTGCGGTTCTACATTTACTGCAAAATCTTTTTC
GAATCCATCTATATATCTGCGGTTCTACATTTACTGCAAAATCTTTTTCRestriction 1 Restriction Clone 1
GAATCCATCTATATATCTGCGGTTCTACATTTACTGCAAAATCTTTTTCGFP_DBP2_M1.ab1(20>990)
4,170 4,180 4,190 4,200 4,210
ACAAATCCATACAAAATTACCCTTTAATTTTTTTTTAACTGAGGACATC
ACAAATCCATACAAAATTACCCTTTAATTTTTTTTTAACTGAGGACATCRestriction 1 Restriction Clone 1
ACAAATCCATACAAAATTACCCTTTAATTTTTTTTTAACTGAGGACATCGFP_DBP2_M1.ab1(20>990)
4,220 4,230 4,240 4,250 4,260
ATTTCTCTCCAAATATCTTCTTTATATTCATTCCACCACTGCTTACGAT
ATTTCTCTCCAAATATCTTCTTTATATTCATTCCACCACTGCTTACGATRestriction 1 Restriction Clone 1
ATTTCTCTCCAAATATCTTCTTTATATTCATTCCACCACTGCTTACGATGFP_DBP2_M1.ab1(20>990)
4,270 4,280 4,290 4,300 4,310
GCAGTTGAGCATTTTGACCAGTTCCAAAGATGCTGCTCAAATTTTTTTC
GCAGTTGAGCATTTTGACCAGTTCCAAAGATGCTGCTCAAATTTTTTTCRestriction 1 Restriction Clone 1
GCAGTTGAGCATTTTGACCAGTTCCAAAGATGCTGCTCAAATTTTTTTCGFP_DBP2_M1.ab1(20>990)
4,320 4,330 4,340 4,350 4,360
CACTACTTTGGAATATCCAATAGACTCCATATCAGTTCCCATAATTAAA
CACTACTTTGGAATATCCAATAGACTCCATATCAGTTCCCATAATTAAARestriction 1 Restriction Clone 1
CACTACTTTGGAATATCCAATAGACTCCATATCAGTTCCCATAATTAAAGFP_DBP2_M1.ab1(20>990)
4,370 4,380 4,390 4,400 4,410
TCTCCAAAATCTTCAAAACTCCATCTTATATCATTACATAAGTCTTTGT
TCTCCAAAATCTTCAAAACTCCATCTTATATCATTACATAAGTCTTTGTRestriction 1 Restriction Clone 1
TCTCCAAAATCTTCAAAACTCCATCTTATATCATTACATAAGTCTTTGTGFP_DBP2_M1.ab1(20>990)
4,420 4,430 4,440 4,450
CATATATGTTGTTATTCTTCCTTAATAATAAATTGCCCTCTGCTGTAAC
CATATATGTTGTTATTCTTCCTTAATAATAAATTGCCCTCTGCTGTAACRestriction 1 Restriction Clone 1
CATATATGTTGTTATTCTTCCTTAATAATAAATTGCCCTCTGCTGTAACGFP_DBP2_M1.ab1(20>990)
4,460 4,470 4,480 4,490 4,500
ATCATAAATGAGTTTTATTTTCAAATATAATTTTCGAAATGTTATATCA
ATCATAAATGAGTTTTATTTTCAAATATAATTTTCGAAATGTTATATCARestriction 1 Restriction Clone 1
ATCATAAATGAGTTTTATTTTCAAATATAATTTTCGAAATGTTATATCAGFP_DBP2_M1.ab1(20>990)
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